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SAFETY OF NOVEL FOODS 
REPORT OF A WORKING GROUP MEETING - 15 DUNE 1984 
During the General Meeting of the International Council of 
Scientific Unions (ICSU) in September 1983 in Warsaw, an informai meeting 
of representatives of the biological unions commented upon the growinq 
and diverse interest in novel and unusual foods: foods or food 
ingredients produced from materials or by processes of conversion not 
known to have been used to any significant extent in human diets or for 
continuous human consumption. 
The ICSU delegates raised the question: Have methodologies been 
formulated adequate to determine th(. safety of novel foods, as above 
defined, for continuous consumption in siqnificant quantities by human 
beings? If so, what are the methods and how widely have they been 
promulqated and accepted? If not, what work is in progress to devise, 
formulate and gain acceptance for appropriate methods, what research is 
necessary, and in the meantime, what cautions should be offered to 
scientists and technologists whose experience and interest is more 
devoted to biotechnological conversion and processing than to human 
nutrition? 
In an attempt to answer these questions, a working group was 
convened under the sponsorship of the International Development Research 
Centre (IDRC) and the ICSU Commission on the Application of Science to 
Agriculture, Forestry and Aquaculture (CASAFA). The group met at the 
IDRC headquarters in Ottawa Canada on 15 June 1984. A list of 
participants is attached as .Aopendix I. 
This report on the meeting consists of the following: 
- Chairman's openinq remarks; 
- Section I: Summary of the six requested presentations; 
... /2 
2 
- Section II: Summary of the discussions that followed the 
presentations; 






In welcoming the members of the Working Group to IDRC, the Chairman 
elaborated on the concerns expressed by the representatives of the ICSU 
biological unions. 
It was noted that specific reference had been made to the processinq 
of agricultural and biological waste materials composed of various 
carbohydrate, cellulosic, lignocellulosic and other organic substances. 
Proposed processes of conversion include aerobic and anaerobic, liquid 
and solid state fermentations employinq a wide range of yeasts, funghi 
and bacteria with thermophiles and mesophiles being of particular 
interest since they can be grown ii tropical countries without resort to 
temperature control by mechanical refrigeration. 
Cereal straw, the by-products of woody plants and other sources of 
lignocellulose are of particular interest because of their abundance. 
The Chairman noted that workers have reported the investigation of 
growing collections of lignocellulytic orqanisms, such as wood-rot 
funghi, collected from tropical sources. Others have proposed thermal 
explosive degradation of lignocellulose followed by alternative 
fermentations of the derived cellulose, lignin and hemicellulose. Other 
researchers are screeninq funghi capable of progressively hydrolyzinq and 
fermenting macro-molecular carbohydrates under tropical conditions. 
Certain species of Aspergillus which showed desirable fermentation 
characteristics were considered a potential hazard-to workers susceptible 
to aspergillosis and related respiratory diseases. Do other thermophiles 
and mesophiles present similar or other hazards? 
In addition to fermentation hy naturally occurring organisms the 
techniques of gene transfer are being proposed as a means of endowing 
familiar species of food yeasts with a capability to both hydrolyze and 
ferment cellulose and other polysaccharides. 
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The extensive publicity given to the biotechnologies in general and 
to various possible novel foods appears to be exciting expectations from 
and encouraging investment in related research. Is sufficient attention 
being given to what is necessary to ensure that whatever novel foods and 
animal feeds result are of a nature and composition that can be 
considered suitable for direct or indirect human consumption? 
In addition to a variety of fermentations, microorganisms and 
substrates proposed for the production of novel foods and animal feeds, 
there is evidence of research to generate novel food plants by somatic 
hybridization and other techniques. Of particular interest are wide 
intergeneric crosses between cultivated and wild species, the primary 
purpose being to generate hybrids tolerant to adverse agroclimatic 
conditions. 
The Chairman pointed out that the questions raised at the ICSU 
meeting and by other scientists are concerned with the availability, 
adequacy and applicability of methods by which to establish and monitor 
standards of quality in novel foods and animal feeds. The concern rests 
not simply with foods and feeds produced under controlled laboratory and 
pilot plant conditions, but with those to be manufactured on an 
industrial scale. 
Since the principal target for many of the novel food and feed 
proposals appear to be the developing countries of Africa, Asia, Latin 
America and the Middle East, it would appear highly desirable that the 
standards of quality and methods of assay and monitoring lie within the 
institutional, material, economic and human resources available. It was 
suggested that the Working Group give consideration not only to the 
availability and reliability of chemical, physical and biological methods 
of determining quality and safety, but equally to the necessary 
resources: what institutional, material and physical facilities and 
equipment and, most important, what human skills are needed reliably to 
apply the methods proposed? What order of cost is implied to establish, 
.../5 
maintain and operate the necessary facilities? 
What particular difficulties are likely to be encountered, 
particularly in producing novel foods in tropical environments? Which 
kinds of novel foods rnay present the greatest hazards to human health? 
In general, what words of caution should be offered to governments and 
potential manufacturers that are beinq encouraged to pursue the 
development and production of novel foods? 
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SECTION I: SUMMARY OF PRESENTATIONS 
1. Presentation by Dr. S. Miller 
The Centre for Food Safety and Applied Nutrition (CFSAN) of the 
U.S. Food and Drug Administration has been approached by some U.S. 
companies interested in producing novel foods, or usinq novel processing 
methods, and has made some studies of the problems these foods may 
present. However, the CFSAN has not corne to grips with these problems in 
an institutional way and has no plans at this time to issue guidelines. 
The feeling is that for the present each novel product must be considered 
on its own merits. This requires some classification of novel foods. 
Five categories are being considered. In order of increasing 
concern they are: 
(a) Novel constructions or processing of traditional food materials, 
eg. irradiated foods; 
(b) Food products that are non-traditional, but on which some experience 
exists, eg. foods derived'from yeasts; 
(c) Products constructed from non-traditional raw materials, eg. funghi; 
such products are of concern both as regards their toxicity and 
their nutritional value; 
(d) Products of chemical synthesis: these are promoted for their 
functional properties but both their potential toxicity and 
nutritional value are of concern. It is now possiliie to produce a 
"bread" with no nutritional value; present regulations do not easily 
cover such a product. 
NOTE: (c) and (d) are of equal concern. 
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(e) Products which are constructed from or consist of orqanisms 
resulting from genetic manipulation. There is concern not only with 
toxicity and nutritive value, but also with the danger of the 
release or escape of genetically modified organisms. 
In assaying for potential toxicity chemical analysis is the most 
reliable first step, provided, as in the case of approved additives of 
known composition, precise methods of analysis exist. Proximate analyses 
for nitrogen, lipid, carbohydrate, fibre and minerai content are 
necessary but do not present a total picture. Computer assisted pattern 
recognition and comparison (using for example modern chromatographic 
techniques) may be a useful guide. 
Toxicological testing of nove foods presents several major 
difficulties. Excess dose rnethods cannot be used for novel foods or 
major food ingredients to be consumed in sizeable quantities over long 
periods of time. Due attention must be given to mutagenesis, 
particularly with genetically engineered organisms. Animal testing 
studies must be multigenerational and beqin at the in utero stage. Tests 
on novel foods must take account of human functionality and possible 
influences upon the immune system, behaviour and general physical 
performance. Before any reliable guidelines can be formulated, the 
probable extent and pattern of consumption over a very wide area will 
need to be determined. 
2. Presentation by Dr. R.L. Hall 
In developing suitable safety tests for novel foods due 
consideration must be qiven to adequate comparison with the familiar and 
traditional foods that novel foods are likely to replace or supplement. 
Food and Drug authorities are becoming increasingly aware of weaknesses 
in existing methods of testing toxicity, the difficulty of detecting 
subtle effects, the inapplicability of the high exposure levels 
customarily used with minor ingredients and food additives to obtain 
observable results with limited numbers of animals, the possible 
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occurrence of false positives and, in the case of complex food mixtures 
possible delayed toxic effects which may be obscured by other earlier 
effects. 
In determining the safety of totally novel foods each food must be 
approached as a separate entity. While reliance may be placed on 
established tests, new methodologies might be introduced that are 
appropriate to the food being examined and its potential pattern of use. 
It is not possible to specify a standard test protocol to cover all 
possible novel foods. 
Table I attempts to indicate the relevante and utility of different 
methods of analysis and assay for four aspects of novel foods: 
(1) toxicity; (2) nutritional value; (3) tolerance; (4) acceptability. 
Column 1 "Toxicity" indicates the extreme difficulty of estahlishing 
safety (i.e. non-toxicity) of a novel food by animal tests. In examining 
novel foods due attention must be given not only to chemical composition 
but to the production methods hy which the foods are to be manufactured. 
Considerable difficulties are presented by concern for individual 
responses among consumers. In this regard it may be necessary to gather 
data relevant to intolerance and allergenic response to traditional foods 
among human populations in different regions. 
In any event, staged and carefully monitored introductions of all 
novel foods is essential. 
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TABLE I 
RELEVANCE OF TESTS FOR SAFETY OF NOVEL FOODS 
NUTRITIONAL 
ASPECT TOXICITY VALUE TOLERANCE ACCEPTABILITY 
METHOD 
PREDICTIVE T - Not done xx 






- PROXIMATE T - xx xx U/I U/I 
N-xx xx U/I U/I 
- IMPURITIES/ T - xx U/I U/I U/I 
CONTAMINANTS N - xx U/I U/I U/I 
- DETAILED/ T - Rare U/I U/I xx 
COMPARATIVE N - xx U/I U/I xx 
METABOLIC/ T - largely x - largely 
PHARMACOLOGICAL known known x U/I 
N - xx xx x U/I 
SHORT TERM TESTS T - xx? rate U/I U/I U/I 
N - xx? U/I U/I U/I 
ANIMAL FEEDING TESTS 
- ACUTE T - Imposs. U/I U/I U/I 
N - Imposs. U/I U/I U/I 
- SUB-CHRONIC T - Not done largely known U/I U/I 
N - xx? 
insensitive xx U/I U/I 
- CHRONIC T - Not done largely known U/I U/I 
N - x? 
insensitive x? U/I U/I 
- HUMAN TRIALS T - largely largely known 
known xx xx 
N - x, Ultimate x, ultimate 
criterion criterion xx xx 
T = Traditional; N = Novel; xx = customary and useful; x = occasionally 
done but value not well established; U/I = Useless/Irrelevant 
SOURCE: Dr. R.L. Hall, President IUFoST and Vice President Science and 
Technology, McCormick & Company Inc. 
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3. Presentation by Dr. Narasinqa Rao 
The ability of many of the less developed countries to implement 
testing and control of non-traditional foods is limited. Dr. Rao 
reviewed India's resources in this respect and discussed how India's 
efforts to develop new or little used foods were beinq adapted to the 
resources available. 
India has emphasized the evaluation of grains and legumes that are 
little known outside India but have a history of local or tribal usage. 
Examination of the nutritional status of selected communities will 
provide evidence on the potential of such crops for wider use. 
They are also trying to increase the yields and production of 
conventional oilseed crops and to evaluate minor oilseed crops. India 
suffers a severe shortage of dietary fats and oils: imports are necessary 
to maintain an average per capita intake of 13 g/day. Tree seeds are 
being tested, as also are the oils extracted from agro-industrial 
by-products including rice bran, rubber seed and tea seed. Toxicological 
tests have been done on various oilseeds; chemical tests for cyclic and 
epoxy fatty acids are being done. 
Some interest exists in producing single cell protein from petroleum 
suhstrates. The principal nutritional interest in India however is in 
increasing the availability of calories rather than in protein 
supplements and there is not a great interest in SCP as a major 
ingredient of diet. 
Gaining acceptability of novel and unfamiliar foods is inevitably a 
source of major difficulty. 
A five year program has started to develop microorganisms high in 
digestible lipids grown on substrates composed of readily available and 
unused biomass. Chemical analysis to determine the fatty acid 
composition of the lipids is generally considered adequate in determining 
wholesomeness. 
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Some macro-algae have been examined as potential food sources but in 
general the acceptability together with high ash and fibre content 
present difficulties. 
4. Presentation by Dr. S. Gunner 
Dr. Gunner expressed agreement with most of what Dr. Miller had 
said. Like the U.S., Canada is not attempting to develop specific 
guidelines for novel foods, but is trying to take a pragmatic approach. 
Where applicable, the controls designed for food additives can be adapted 
to novel foods. The Health Protection Branch of Health and Welfare 
Canada grades novel foods into three categories: 
(1) Those of known history; very little needed in the way of safety 
requirements, eg. pea protein extracts and isolates; 
(2) Intermediates, eg. concentrated protein products from rapeseed or 
soybean; 
(3) Radically new products, eg. SCP or genetically modified products. 
Health and Welfare Canada tries to avoid an overly rigid approach to 
food evaluation preferring to judge each new or modified food upon its 
merits, a philosophy which has worked satisfactorily in formulating and 
implementing Canada's food additives legislation. 
Future action will probably involve: 
(1) Development of a hierarchy of needs by means of which the degree of 
evaluation and testing required for a novel food can be decided on a 
case by case basis, perhaps from a "decision tree"; 
(2) Refining existing tests for application to novel foods; 
(3) Emphasis on factors that will arise as a novel food is introduced 
into common usage. A need is foreseen for close monitoring of 
consumption, and for gathering data on reports of allergies and 
intolerances. Animal feeding tests will not detect these adverse 
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reactions; new testing methods are needed, possibly including 
cultures of human tissue. 
5. Presentation by Dr. N. Scrimshaw 
Dr. Scrimshaw gave a brief history of the Protein Advisory Group's 
(PAG) Guidelines 6, 7, 12 and 15 (Appendices 2, 3, 4 and 5) and outlined 
the changes made during the recent review of these quidelines by the 
United Nations University (UNU). Points of major concern and a number of 
examples garnered from Dr. Scrimshaw's experience were outlined. 
Many traditional foods induce allergenic or intolerance responses in 
sonie individuals. Animal feeding tests are of no value for detecting or 
quantifyinq these reactions. What frequency of such complaints should be 
tolerated in test human subjects or in the generai consuming public is 
far from beinq decided. 
It is generally recognized that toxicological studies in 
experimental animals and practical feeding studies in domestic animals 
are satisfactory for determining the suitahility of novel protein sources 
for animal feeding, but do not assure their acceptability and toleranee 
for human feeding. It is sometimes suggested that the products from 
animais fed novel protein sources should be submitted to biological 
testing, but this is impractical. The best assurance cornes from testing 
of the material before feeding. However, any substances detected in 
abnormal quantities in these products can be submitted to biological in 
vivo or in vitro evaluation. For this reason there should be an initial 
identification of any abnormalities in physiological state or composition 
of the carcass and organs of animais fed unusual feeds. 
Before embarking upon tests of novel foods by human subjects, a 
comprehensive and detailed evaluation needs to be made of the raw 
materials, processes of production and conversion, chemical analyses 
including both macro and micro components, and results of feeding tests 
over a range of laboratory animais. 
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The incorporation of cottonseed flour containing a low level of 
gossypol into the vegetable mixture INCAPARINA in Guatemala gave rise to 
no detectable effects in animal feeding studies, that included 
pathological examination of testes and other tissues, or when fed to 
human subjects. Years later it was demonstrated in China that gossypol 
inhibits spermatogenesis at similar levels. Presumably, the cooking to 
which the INCAPARINA is submitted sufficiently inactivated the gossypol, 
but clearly the animal testing was a wise precaution and would have 
detected spermatogenic effects. 
The Clinical Research Center at MIT has conducted extensive tests of 
yeast and bacteria products grown on a variety of substrates ranging from 
molasses and sulfite to alcohol and normal alkanes. Although ail of 
these had been extensively studied in acute and chronic tests with 
experimental animais, most of them caused some gastrointestinal or 
allergic response as originally fed. It was usually possible to find a 
processing procedure that inactivated the substance responsible. 
For example, an ordinary C. utilis grown on beet molasses and used 
routinely in processed foods in Europe caused a high prevalence of skin 
allergies when heat shocked at 80 degrees C. to reduce its DNA content. 
This effect was completely eliminated by raising the temperature of the 
treatment to 140 degrees C. for an even shorter period. Both products 
were completely free of detectable adverse effects when fed to rats. 
These results further illustrate the influence of and need for careful 
monitoring of processing conditions. 
Yeasts grown on normal alkanes have a higher content of C-14 to C-18 
hydrocarbons than most foods. However, they are no different from those 
in the minerai oil used in much higher concentrations without restriction 
to polish fruits, coffee beans etc. and have no adverse pathological 
implications at the levels involved. More attention has been paid to the 
presence of odd-numbered carbon chain fatty acids in micro-organisms at 
higher concentrations than in most common foods and their similar 
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presence in the fat of animais fed alkane qrown yeasts. However, 
exhaustive studies that have involved pot only feeding but also 
investigations at the ribosomal level, have shown that there is nothinq 
abnormal about the metabolism of these fatty acids. Moreover, they are 
normally present in some common foods. Despite this, and then acceptance 
for animal feeding in other European Countries, activist groups in Italy 
have successfully blocked approval of these yeasts. 
The revised PAG/UNU guidelines should now be widely circulated and 
examined critically so that they can be kept up-to-date through periodic 
revisions. A joint task force of the relevant International Scientific 
Unions carried out the recent revision and similar task forces should be 
appointed for this purpose in the future. 
6. Presentation by Or. J.W. Bridges 
Dr. Bridges outlined the organization of the UK Advisory Committee 
on Novel Foods, which is advisory to both the Ministry of Health and the 
Ministry of Agriculture, Fisheries and Foods, and discussed its working 
procedures and philosophy. The Committee tries to work with industry and 
avoid adversarial situations. Companies are not legally required to 
submit data to the Committee but industry itself tends to favour full 
submissions. The Committee has now completed a draft set of test 
quidelines for novel foods (Appendix 6). The UK Committee considers that 
novel foods should be considered quite separately and independently from 
food additives in formulating legislation and safety for guidelines. On 
the other hand, the Federal Republic of Germany proposes to modify 
existinq food additives safety quidelines for application to novel foods. 
Some particularly interestinq aspects of the UK guidelines include: 
(1) They accept use of only two test levels in animal feedinq trials; 
(2) Acute toxicity data are not required; 
(3) Metabolic studies are not emphasized except for known minor 
components; 
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(4) Broad comprehensive testing protocols are required each specifically 
designed for the novel food under consideration. 
In response to a question, Dr. Bridges indicated that his Committee 
is encouraging close cooperation with medical authorities and general 
medical practitioners who work in the regions where novel foods are being 
test marketed. 
NOTE: A copy of the British Memorandum is attached as Appendix 6 
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SECTION II: SUMMARY OF DISCUSSIONS 
The following is an attempt to sumnarize the principal points of 
discussion and recommendation. 
Public Attitudes Towards Food Safety 
Several participants noted that concerns expressed by the general 
public or promoted by public interest groups may inhibit the manufacture 
and test marketing of novel foods even in cases where scientific evidence 
suqqests that adequate safety precautions have been observed. Examples 
cited included: (1) objections to lipids, synthesized by microorganisms, 
that contain an odd number of carbon atoms, in spite of the absence of 
any laboratory evidence of toxicity or unwholesomeness; (2) the 
government of an African country discouraged the production of triticale 
on the grounds that it contained "toxic" alky, resorcinols in spite of 
(i) analytical data which showed the levels to be lower than what is 
present in the rye grain and (ii) animal feeding tests carried out in 
Canada in which animais received five to ten times the intake of alkyl 
resorcinols present in rye flour withoui adverse effects. 
Allocation of Costs of Testing for Safely 
Though it is unlikely that small-scale manufacturers could afford 
the vert' high cost of the tests requirec to demonstrate safety in novel 
foods, it was generally aqreed that in most instances the cost of 
demonstrating safety must be borne by the company proposing to 
manufacture and market. It was pointed out that in most developing 
countries relatively few manufacturera could afford the total cost of 
following such safety quidelines as are recommended by the UK Committee. 
Where it may be in the national interest to consider the introduction of 
novel foods, much of the cost of determining and continuously monitoring 
safety durinq production, distribution and consumption would have to be 
underwritten by government agencies. In general, however, the Working 
...117 
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Group believed that the hiqhest priority should be qiven to increasinq 
production of traditional foods and the processinq of familiar well 
accepted raw materials. Unfamiliar proteins are particularly liable to 
lead to undesirable reactions. 
The risk and high cost of litigation in the U.S. and other 
industrialized countries was discussed at some lenqth. Consumers groups 
are well organized though not always as well informed as they miqht be. 
Food science organizations in many countries are givinq more attention to 
public education and information concerning the composition and quality 
of both traditional and comparatively novel foods. Nevertheless, many 
prejudices and misconceptions are still evident which, together with 
recent court decisions in the United States that have emphasized company 
liability, may seriously constrain future attempts to introduce novel 
foods. 
Tests and Testinq Procedures 
A number of participants recommended an increased emphasis on 
chemical analysis of novel foods. Experience with irradiated foods has 
shown that detailed chemical analyses were helpful. Dr. Miller stated 
that the CFSAN laboratories were explorinq the possibility of developing 
analytical patterns for traditional foods which miqht ultimately be used 
for comparison with those of novel foods; unusual components in the 
patterns might then be selected for further study. While analytical 
techniques may help define nutritional quality and some toxic aqents 
possibly present in novel foods it was noted that they are unlikely to 
substitute for toxicoloqical testinq in view of the possible presence of 
chemicals whose toxicity has yet to be recognized. 
The reasons for the introduction of novel foods may be significantly 
different in various countries of the world. For example, in the U.S. 
and other industrialized countries where people would like to eat as much 
as they wish without gaininq body weight, research has been devoted to 
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the production of products which closely resemble in appearance and 
flavour traditional foods but which contain reduced or no nutritive 
value. The use of synthetic low calorie sweetening agents in soft drinks 
and confections is widely familiar. A new generation of novel foods may 
provide substitutes which reproduce the technoloqical and functional 
properties of carbohydrates, lipids and proteins but which are devoid of 
any nutritive value. These must be considered quite distinctly from 
proteins and lipids synthesized by microorganisms from various biomass 
substrates. Conventional tests by laboratory animais of nutritive value 
and toxicity cannot be considered rince there will be no growth response 
from a material which contains no nutritive value. 
Dr. Scrimshaw reported that the most common adverse effects noted in 
human testing of novel foods were gastro-intestinal disturbances and 
cutaneous rashes. In yeast and bacteria derived products most of the 
gastro-intestinal problems related to the nucleic acid content can be 
overcome by various procedures to reduce the content. However, these 
seem frequently to release relatively low molecular weight proteins that 
cause allergic responses, and require further processinq to remove. 
Thirty day feeding studies have been sufficient to detect these problems 
and longer tests have had no advantaqe. One problem is that the 
processing to remove allergic substances should be closely monitored and 
there is no satisfactory way beyond process control to do so. When 
individuals with leukocytes sensitized to the antigen are available, a 
lymphocyte stimulation test can be used, but this is complex and costly. 
Moreover, the sensitivity wears off a few months after exposure. 
The need for information on the frequency with which intolerance and 
allergenic reactions occur with traditional foods was noted by several 
participants. Dr. Miller reported in some studies that 5% to 60% of 
sampled populations reported intolerances to various foods. Severe 
intolerance reactions to a novel food justifies its immediate rejection, 
but rejection because of mild reactions in a few test subjects is hard to 
justify without baseline data gained from studies of traditional foods. 
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Two participants noted the need for stud.ying the response of the 
gastro-intestinal tract during human testing of novel foods. The long 
resistance times in humans may permit development of adaptive bacteria 
and production of foreign substances. These would not be detected in rat 
feeding trials because of the shorter residence time in the gut. 
The inappropriateness of a safety factor approach for a novel food 
intended for use as a major human food was mentioned. The 
inapplicability of the excessive dose approach to toxicity testing of 
such products in laboratory animais was also recognized. Dr. Scrimshaw 
emphasized that in human testing dual control groups are recommended 
especially if excessive diarrhea is evident. 
The minimum number of humans that must be exposed during a 
preliminary feeding test was discussed. Dr. Holub noted that a test on 
25 people may not detect a 5-fold elevation in toxicity. Dr. Scrimshaw 
replied that the fewest possible number should be exposed in a 
preliminary trial. He recommended a compromise of 25 to 30 persons in a 
double blind, cross-over test. Thus only 12 to 15 humans would be 
exposed in the first sequence. To date, preliminary experiments of this 
size have served to send ail projects "back to the drawing board". 
Close Monitoring at All Times 
Several participants emphasized the need for close monitoring of any 
novel food approved for use, includinq monitoring of production, 
processing, marketing and exposure (consumption). Points raised in this 
regard included: 
(1) The necessity of assuring that the novel food being marketed is 
identical in ail respects to the material produced and tested in the 
laboratory; quality control procedures for novel foods will need to 
be more stringent than is required for traditional foods with which 
a long experience has been gained. 
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(2) Monitoring should give special attention to micro-flora, 
particularly in fermented foods since undesirable organisme can grow 
together with the organisms designed and intended to brinq about the 
fermentation desired. 
(3) Distribution and human consumption of novel foods should be phased 
in gradually and any adverse affects noted and reported by competent 
medical authorities. It was emphasized that controlled exposure to 
a major novel food will be more difficult to control than the 
consumption of permitted food additives. 
(4) Particular caution must be exercised in distributing novel foods to 
such vulnerable groups as pregnant and nursing women, younq 
children, people who are sick, the malnourished and those who have a 
history of specific intolerances and allergies. 
Potential Risk to Workers 
The potential risk to workers in factories producing novel foods was 
discussed. Many live organisms are more danqerous when inhaled than when 
ingested, a fact illustrated by experience with what appeared at first as 
a particularly suitable Aspergillus. This organism both hydrolyzed and 
fermented root starches, being most active at close to pH 3.5, converting 
inorqanic nitrogen to a crude protein (dry weight) content of ca. 35%. 
Unfortunately, the Aspergillus formed aerosols which could be extremely 
hazardous if inspired by persons susceptible to aspergillosis. 
It was also noted that nome flavou- ingredients and cereal grain 
flours may be allergenic in contact with skin and respiratory tissue 
though harmless when ingested. 
Possible Adverse Effects of Rigid Protocols 
The possible hindrance that could be caused by strict, inflexible 
controls on the most exemplary of novel foods was of concern to some 
participants. Excessive testinq could put unnecessary demand on the 
economic, institutional and human resources of a developing country. 
Rigid protocols can cause long delays in the introduction of novel foods. 
...121 
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Corroborative to the above, a concensus developed that all 
guidelines for the safety of novel foods should be as flexible as 
possible. Tests should be required on a pragmatic, case by case basis 
(Dr. Gunner's "decision tree" idea). In evaluating the safety and 
suitability of novel foods, regulatory agencies will need to consider the 
whole body of evidence and not attempt to rely upon any specific or 
narrowly defined test. 
A GRAS List for Foods 
A suggestion was made that it miqht be possible and desirable to 
develop a GRAS (generally recoqnized as safe) list of novel food 
constituents, and that such a list might allow some testinq to be 
bypassed for some novel products. Discussion of this point centered on 
the activity of JECFA (Joint Expert Commission on Food Additives), an 
FAO/WHO body, and of the Codex Committee on vegetable proteins. Dr. Hall 
pointed out that the U.S. GRAS list is defined as "safe under conditions 
of intended use", the intended use being clearly specified. Furthermore, 
the GRAS list was developed mainly to cover food additives and 
micro-ingredients rather than novel foods to he consumed in relatively 
large quantities. While recognizing the value of the GRAS concept in the 
U.S. context in which it is applied, the working group was not able to 
resolve how such a concept might be applied to novel foods developed for 
wide-scale consumption. 
Draft Guidelines 
The draft guidelines presented by Drs. Scrimshaw and Bridges 
(Appendices 2 throuqh 6) were compared and discussed in some detail. It 
was emphasized that these guidelines should not be interpreted as 
advocating the use of novel foods. One participant suggested that the 
guidelines should differentiate between "essential" and "desirable" tests 
but a case-by-case approach seemed to be preferred. Dr. Scrimshaw noted 
the need for international guidelines even though various countries may 
prefer to develop their own. In answer to a question, Dr. Scrimshaw 
indicated that the UNU was willing to continue to take responsibility for 
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periodic revisions of its guidelines for novel foods and asked whether an 
attempt should be made to consolidate them with the new British 
guidelines beinq developed. Participants aqreed that harmonization would 
be desirable but that they did not need to be identical. The present 
revised UNU guidelines need the addition of suggestions for manufacturing 
and handling and more emphasis on the graduai introduction and monitoring 
of the novel product. 
Need for Continued Research 
The need for more research was repeatedly mentioned. Dr. Miller 
remarked that "an incredible amount of research is needed, much of it 
very difficult and complex". He asked how can the effect of a novel food 
on human functionality including the immune function, and upon human 
behaviour be determined. The research needed will call for a very high 
standard of scientific capability combined wit'1 a practical working 
knowledge of the nature, process of manufacture and probable pattern of 
distribution and consumption of ail novel foods under consideration. 
Several specific proposals for future ;'esearch were offered (see Section 
111.3). 
Human Resources 
Though in many countries the physical, laboratory and material 
resources are inadequate to the task of developinq and continuously 
monitoring the safety of novel foods, most evident throughout the world 
is the need for increased, suitably trained human resources. It was 
noted that in Canada the number of the PhDs in agricultural sciences 
retiring this year from. the Canadian government and universities will be 
roughly double the number of new doctoral graduates. Throughout the 
world the proportion of qraduates in social sciences, humanities and the 
arts is increasing in relation to graduates in natural, physical, health 
and agricultural sciences. There is eiidence to suggest that national 
research institutions often display greater enthusiasm for the 
development of new technologies than for the continued monitoring of 
safety and desirable quality. Dr. Miller expressed the opinion that the 
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scientific disciplines taught in universities to food science graduates 
are not adequate to cope with the immense complexity of the novel foods 
and manufacturinq processes foresEen in the future. Of particular need 
are graduates competent in both tcxicology and in nutritional 
biochemistry. Developing countries in particular need to establish 
reliable food requlatory agencies before embarking upon extensive 
research and development programs in pursuit of novel foods. 
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SECTION III: RECOMMENDATIONS 
1. Recommendation Concerninq the Consolidation of Guidelines 
The working party recommended that the UNIJ continue its efforts to 
produce international guidelines for the testinq of novel foods. As a 
first step it is suggested that the present PAG/UNU guidelines be revised 
and consolidated, taking into consideration the UK draft document and the 
discussions of this working party. The revised document should, to the 
greatest extent possible, include quidelines for the conditions of 
manufacture. Guidance for the cautious introduction of any approved 
novel food might also be included, bearing in mind the social and dietary 
factors that may influence food acceptability and tolerance. 
It was also recommended that the British Committee on novel foods 
take account of the concerns expressed hy the working group durinq the 
further revision of its guidelines. 
Or. Hall, President of the International Union of Food Science and 
Technology (IUFoST) and Dr. Scrimshaw, a past President of the 
International Union of Nutrition Sciences (IUNS) agreed to establish 
joint working groups to consider specific aspects of the subject of the 
safety of novel foods, in particular how best to apply the "decision 
tree" approach. 
Given the importance of reliable methods of chemical analysis it was 
suggested that the International Union of Pure and Applied Chemistry also 
be invited to cooperate with IUFoST and IUNS. 
2. Recommendations to National Governments 
Because of the complexity of the subject, the many uncertainties by 
which it is constrained, the extensive facilities required and the high 
cost of determining and maintaininq safety in uniquely novel foods, all 
governments are recommended to approach novel food development with 
considerable caution. 
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Every government must individually weigh the risks versus the 
benefits inherent in the introduction of a novel product. A major factor 
to be considered in making this decision is the availability of resources 
essential for the tank: information/data, research, technical, human and 
institutional. Only when such resources are adequately available, and 
backed by an effective system for technological and scientific training, 
can the full benefits be gained from the successful introduction of a 
novel food. Appendix 8 pives a summary of the approximate costs of 
testing various categories of novel foods, as well as the human and 
financial resources necessary to establish a minimum testing laboratory. 
Establishment of the necessary infrastructure to assure the safety 
of all food produced or marketed is an essential step towards the WHO 
goal of full health for all persons. Health for all requires adequate 
food for all, and the assurance of safe food supplies requires the 
appropriate infrastructure. Because of high colts of research, limited 
resources, and the large amount of research that needs to be done, 
unproductive duplication of efforts should be minimized by encouraging 
effective international collaboration. 
3. Recommendations Reqardinq Research 
The following is a summary of research priorities suggested durinq 
the course of the meeting as well as research proposals subsequently 
submitted by the members of the Workinq Group: 
(A) Development of more sensitive/appropriate model systems. 
Present routine testinq methods are, for various reasons, not 
effective in detecting a number of likely adverse effects of novel foods 
in man such as: 
- behavioural changes, e.g. irritability 
- immunoloqical modifications, e.q. allerqy 
- skeleto-muscular alterations, e.g. athritis 
- gastrointestinal intolerance, e.g. associated with gut microfloral 
changes. 
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Priority should be given to developing systems/detection methods for 
these lesions. It may well be that the rodent strains presently used in 
other aspects of toxicology are not appropriate to detect the above 
effects and that other species should also be examined. However, in the 
case of gut microfloral changes it may be possible to develop a more 
appropriate model by seeding gnotobiotic animais with a microflora 
"cocktail" which resembles that of man. 
The test systems also need to be improved for the assessment of the 
mutagenicity/genotoxicity of novel foods, as well as the immune response 
to foods both in vivo and in vitro. 
(B) Further studies of the background incidence of diet-induced disease 
in man and laboratory animais are recommended. 
In planning research on the safety of novel foods it must be borne 
clearly in mind that the scientific community is profoundly ignorant of 
the risks associated with traditional foods. Doll and Peto in "The 
Causes of Cancer" (Oxford Univ. Press, 1981), for example, have suggested 
that in the U.S. 40% of cancer in males and 57% in females is 
attributable to diet. The precise factors involved are not known. Other 
diseases may likewise be linked to diet. Therefore the objective of 
toxicity testing of novel foods is not a search for near absolute safety 
as with food additives, but an attempt to ensure that novel foods are at 
least safe as, or safer than, the traditional foods they replace. 
In order to identify the toxic properties of novel foods, it is most 
important to establish the adverse effects on human health of 
"traditional" foodstuffs both in man and in the animal models used in 
safety evaluation studies. Human studies should in particular consider 
the effects identified under (A) above. 
(C) Analytical profiles of common foods are needed. 
Information on the "unknown" constituents of foods for which there 
has been extensive human experience is needed in order to identify 
abnormal structures. This data is required to: 
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a) ascertain which constituents in a novel food man has not been 
previously exposed to; 
b) identify components of present foodstuffs which may require some 
toxicological assessment; 
c) improve quality control and product identification criterion. 
Food constituents include a wide variety of chemicals usually 
present in traditional foods at a relatively low level. Some of these 
constituents display significant toxicity and if ingested at high levels 
may lead to disease in animais and possibly man. Several publications* 
describe known toxicants that occur in foods and new suspects are 
continually appearing in the scientific literature. There is a need to 
list these food constituents with an assessment of their toxic properties 
where known and to decide which of them are of sufficient concern to 
warrant particular study in novel foods. 
Research is also needed on methodologies for identifying chemical 
differences between novel foods and those of the naturai food matrix. 
(D) Development of effective post marketing surveillance systems. 
Because of the large numbers and wide range of population involved, 
and the considerable potential duration and frequency of exposure which 
may occur with a novel food, monitoring for related adverse effects is 
essential. Pilot studies are needed to develop the most effective 
surveillance systems of novel foods following commercial manufacture and 
distribution. 
(E) Structure/activity relationship for "abnormal" classes of food 
constituents. 
There are several classes of constituent which are commonly 
considered to be of toxicological concern, e.g. odd numbered carbon chain 
fatty acids, cyclic fatty acids, long chain hydrocarbons. It would be 
valuable to assess the actual toxic properties of such materials to 
enable us to move to a position of prediction for related substances. 
* Toxicants naturally occurring in foods: National Academy of Sciences 
(USA) 1973. 
Toxic constituents of plant foodstuffs: I.E. Liener (Academic Press) 
1973. 
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(F) Early detection of adverse effects in man and animais. 
If simple detection methods could be developed for identifying the 
development of a serious adverse reaction at an early stage, i.e. when 
any lesion could be remedied by withdrawal of the offending agent a major 
barrier to the introduction of novel foods would be overcome. These may 
be biochemical indicators of normal/abnormal functionality, useful at 
dose levels well below those producinq apparent adverse effects. 
Ideally, the same methods should be equally applicable to man and common 
animal models. 
The most sensible approach would appear to be in the identification 
of changes in the profile of intermediary metabolism products in 
biological fluids produced by particular chemically identifiable novel 
foods. Thus, for example, for a novel carbohydrate the study would focus 
on changes in key intermediates (particularly at the rate limitinq steps) 
in carbohydrate metabolism. Work would also of course be required to 
establish the relationship between particular changes and subsequent 
development of recognisable disease. Once the validity had been 
established of monitoring such changes as an early indicator of disease, 
it should be possible to develop appropriate alternative in vitro test 
systems. 
(G) Methods for testing the nutritional quality as well as the safet.y of 
novel foods are required. Tests for macronutrients (especially 
carbohydrates and fats) need to be defined and standardized. 
(H) Research is suggested in determining the amount of modified DNA that 
is released when dealing with genetically modified products. Methods of 
controlling the release of the DNA to the environment must be 
investigated. 
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CONCLUSION 
It is clear from the foregoing that no simple straightforward and 
inexpensive protocols exist by which to determine the safety of uniquely 
novel foods for continuous consumption in significant quantities. The 
evidence strongly indicates, particularly for developing countries which 
possess a modest scientific resource, that greatest priority be given to 
traditional agriculture and to the increased production of familiar foods 
rather than to the synthesis of or conversion of unfamiliar materials 
into novel foods. 
Such methods of assessing safety as are available and are discussed 
above require extensive and expensive resources, resources not available 
in many countries. 
Finally, under no circumstances should the poor people of the world 
be encouraged to be the test consumer market for novel foods that have 
not been demonstrated as safe and which have not and probably would not 
be considered acceptable by more affluent communities. 
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Reprinted from: Food and Nutrition Bulletin, Vol. 5, No. 1, 1983 
PAG/UNU GUIDELINE No. 6: PRECLINICAL TESTING OF NOVEL SOURCES OF FOOD 
Novel foods are defined as those not previously eaten by a 
human population, and that cannot be considered to be 
minor processinq variants of conventional food This guide- 
line is d rected towards commonly used foods processed 
by new techniques and to raw materials not so far used as 
human food either directly or by inclusion in food prod- 
ucts. Similar attention needs to be applied to new va- 
rieties of conventional foods or those that have been genet- 
ically changed. Clear examples for application of the guide- 
lines are new foods developed by isolation from conven- 
tional sources by unusual techniques, and yeasts, bacteria, 
molds, or algae, i.e., the so-called single-cell proteins. Il is 
recommended that ail new foods, including proteins, be 
evaluated with respect to their safety for use and nutri- 
tional value before application as a human food source. 
Il is intended that this guideline serve as a general recom- 
mendation rather han as a series of mandatory proce- 
dures. The guidelines have been developed in general terms 
to describe the categories of data that need to be provided 
in some cases, but not necessarily in ail. Thus, processes 
involving the use of solvent extraction or unusual heating 
conditions, or the utilization of food additives in a variety 
of combinations, would not require a full preclinical eva- 
luation despite possible changes in digestion, absorption, 
or metabolism. 
The development of a protocol for a specific food mate- 
rial will depend upon ils similarity to a conventional food, 
the kind of technological process applied in ils prepara- 
tion, and the conditions of ils intended use as prepared 
for consumption. Prior history of safe use may be taken 
into account in the evaluation of a novel food proposed 
for general consumption, but this atone is flot necessari- 
ly sufficient to preclude adequate preclinical testing by 
currentty available, more objective, laboratory animal feed- 
ing studies. 
The extent of animal testing considered necessary before 
undertaking trials in human subjects will depend on the 
degree of novelty of the food. In the event that the obser- 
vations and resuits of a preclinical appraisal of a novel 
food are to be submitted to e regulatory or institutional 
egency as e basis for clinicat trials, il is advisable to review 
the proposed protocol in advance with such en agency in 
the interest of saving time and effort. In principte, prod- 
ucts intended for incorporation into animal feeds may 
not require such extensive testing as is suggested for hu- 
man foods, but Guideline 15 should be consulted for tests 
considered essential. 
The physical and chemical identity of the industrial prod- 
uct shouid be established to be essentially the same as 
that of the material tested experimentally. To be truly sig- 
nificant, the studies should be conducted on the product 
as made on a production scale rather Chan by iaboratory 
batch. Where this is not possible, the process used to 
produce the test material and ils spec fications should 
not be significantly different from tne process and prod- 
uct to be marketed. If the organism or source material 
has been genetically modified, sonie of the peclinical 
and clinical studies may require repetition. However, mi- 
nor variations in processing conditions need not necessi- 
tate repetition of the entire series of preclinical or clini- 
cal studies. Attention must be given to contaminants eri- 
sing from extraction or refining, as weil as reaction prod- 
ucts resulting from heat processing. Substances used as 
lubricants or binders (e.g., in texturization) shouid also be 
considered in this connect on. 
When evaluating a new product, the following categories 
of information are likely to be needed: 
1.1 Specification of the material. This is a basic require- 
ment, il includes a description of how the product is 
produced, the resuits of chemical and microbiological 
analyses, and details of manufacturing specifications 
1.2 Nutritional value, as predicted from chemical compo- 
sition, with particular emphasis on nutritional value, 
bioavailabiiity, and digestibility obtained in vivo. 
1.3 Sanitation, with respect to the source of the raw ma- 
terial and the conditions under which il is processed. 
Hygiene aspects as well as potential pathogenicity, 
if appropriate, shouid be taken into account 
1.4 Toxicologicaf safety, as predicted from information 
concerning methods of production, chemical and 
physical properties, content of micro-organisms and 
their metabolites. Toxicological studies in laboratory 
animais may be required. The extent of the preclini- 
cal testing programme shouid be decided for each 
new product, based on e consideration of ils source, 
composition, and the nature of the process employed 
in ils production. As exemples, the species of fish 
used for the production of fish protein concentrate, 
the micro-organisms used as single-ceil proteins, and 
the extraction systems employed in processing, may 
determine how much preclinical evaluation is requi- 
red. Choice of procedures shouid be exercised with 
judgment based on expérience. A product intended 
for use as a milk substitute or a weaning food will de- 
mand additional preclinical evaluation compared to 
products intended for use by older children or adults. 
1.5 Technological and physical properties from the point 
of view of incorporation of the product into current- 
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tly acceptable foods, or the fabrication rite new food 
items. 
Tests and procedures to be used are. 
2.1 Chemical analyses to define the approximate compo- 
sition of the material, including the presence of con- 
taminants, pesticide residues, solvants, naturally 
occurring or adventitious toxins, specific additives, 
and natural components with unusual structure. 
2.1.1. Proximete composition, i.e., moisture (and 
total solids), total nitrogen, "fat" (ether 
extract), ash, crude fibre, and "available car- 
bohydrate". 
2.1 2 Protein 
a) The nitrogenous components should be hy- 
drolyzed and the amino acid spectrum de- 
termined. The amino acid composition 
should be expressed per 16 g N. Since ly- 
slne is the principal (although not the only) 
essentiel amino acid likely to become 
bound and thus unavailable as a result of 
heat processing, the slightly modified Car- 
penter method is especially useful as a 
quality control procedure (1). 
b) The presence and amount of non-protein 
nitrogenous components such as glu- 
cosamines, amides and amines should be 
determined, particularly in the case of 
products derived from animal sources. 
c) The content of nucleic acid should be de- 
termined in single-cell proteins. 
2.1.3. Fat 
The solvent extract should be analysed for the 
presence and content of triglycerides, unsapo- 
nifiable lipids (steroids) and phospholipids. If 
the ether extract is greater thon 1 per cent, 
the fatty acid profile should be determined; 
the ratio of polyunsaturated to saturated fat- 
ty acids should also be calculated. Single-cell 
proteins derived from petroleum hydrocar- 
bons should be analysed for total and carcino- 
genic polycyclic aromatic hydrocarbons by a 
suitablequantitative method. 
2.1.4. Ash 
Ash should be analysed for its content of cal 
cium, phosphorus, iron, iodine, alkali and al 
kaline earth elements. and heavy metals. Prod 
ucts of marine origin should also be analysed 
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for mercury, arsenic, and fluorine. In the light 
of concern oyer mercury contamination of 
fish from lakes, streams, and marine waters, 
attention should be directed to the possible pre 
sence of inorganic and particularly alkal mercu- 
re and cadmium in protein concentrates derived 
from fish or algae. 
2.1.5. Undigestible Meterial 
True digestibility should be defined, and the na- 
ture of the undigested material ascertained. 
Exemples are cellulose, hemicelluloses, pectic 
substances, gums, lignin, and some other cell 
wall-associated substances. While such indigest- 
ible material may interfere with the absorption 
of certain nutrients, il may, on the other hand, 
be beneficial in e way similar to dietary fibre. 
2.1.6. Vitamins 
Analyses should be conducted for ail of the ma- 
jor vitamins except those for which e low lipid 
content or instability under processing condi- 
tions indicates little likelihood of their presence 
in significant amounts. 
2.1.7. Food Additives 
Food additives used should be declared and lev- 
els specified, based on quantitative analyses. 
2.1.8. Processing Damage 
Useful information concerning the affect of heat 
on the product may be obtained not oniy by 
determinations of available lysine, but also be 
products of the Maillard (browning) reaction. 
Understanding of the effect of alkali treatment 
of the product may be obtained by the determi- 
nation of lysinoalanine. 
2.1.9. Miscellaneous 
Depending upon the nature of the raw material 
and the conditions employed in ils production, 
special analyses of the product should be con- 
ducted for: 
a) Solvant residues, such as polycyclic or chlori- 
nated hydrocarbons, 
b) Pesticide residues, 
c) Naturally occurring toxic substances, e.g., 
gossypol, haemagglutinins, and marine to- 
xins (il should be noted that there are no sa- 
tisfactory non-biologicel tests for the latter 
category of substances). 
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2.2 Microbiological examination is necessary for viable 
both pathogenic and non-pathoge- 
nic, aerobic and non-aerobic, vegetative, and spore- 
forming. In the case of single-cell protein, the micro- 
biological tests should also indicate the taxonomic 
and potentiel pathogenic status of the organisms 
grown, and the sanitary nature of the fermentation or 
processing conditions. These proteins should contain 
no viable cells of the producing organisms, thus eli- 
minating any problems of pathogenicity. 
2.3 Nutritions/ Eva/uetion 
Gross and available energy should be defined. 
The value of a protein product in promoting growth 
and nitrogen retention may be obtained with young 
rats or other laboratory animais when fed as a sole 
source of protein or as a supplement to other foods. 
The digestibility of a protein product should be deter- 
mined in vivo. For e description of the nutritional 
evaluation of protein fonds, including their energy 
assessment, see Reference 1, Chapter 5. 
2.3.1. Protein quality studies may be conducted 
with young rats or other laboratory mammals, 
to indicate the value of e protein product for 
promoting growth and nitrogen retention 
when fed as the sole source of protein and as a 
supplement to others foods. 
2.3.2. Digestibility of the protein product is best de- 
termined in vivo. Investigations to determine 
the rate and degree of hydrolysis by pepsin 
and pepsin plus trypsin in vitro may be of va- 
lue to simulate conditions within the humain 
gestrointestinal tract. Calculations based on 
the essentiel amino acid content of enzymic 
hydrolysates have been adapted for estima- 
ting the biological value (utilisation) of pro- 
teins. 
2.4 Safety Evaluation 
The identity and reproducibility of the test material 
must be established with that produced commercial- 
ly by chemical and other relevant procedures. Safe- 
ty evaluations using such test materials are based on 
feeding studies in rodents and other experimental 
mammals. Il is assumed that the data will be required 
for regulatory approval purposes, and therefore any 
reports of investigations submitted must include full 
deuils and data for control as well as test groups 
and appropriate statistical analysis of the findings. 
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Brief descriptions of the observations and conclusions 
are not acceptable. The initial short-term studies 
should be followed by long-terrn tests, as appropriate, 
to define the presence of toxic substances. 
Attention should be given to the following: 
2.4.1. Natura/ly-Occurring Toxic Substances 
Naturally-occurring toxic substances found in 
plants include carcinogens (e.g., cycad nuts, 
oil of sassafras), goitrogens (Brassica species), 
haemagglutinins now calied lectins (e.g., pha- 
seolotoxin in légumes), lathyrogens (e.g., vetch, 
sweet peas), cyanogenetic glycosides (cessava 
and certain beans and nuts), and estrogens (in 
seeds and leafy vegetablvs). Marine sources of 
protein, such es fish or shellfish and the algae 
or plankton on which they feed, may contain 
highly toxic substances. Naturelly-occurring to- 
xic agents can he avoided either by care in the 
sélection of the raw materials or by appropriate 
methods of storage, heat processing, or extrac- 
tion. 
2.4.2. Microbial Toxins 
Raw materials subject to microbial contamina- 
tion and spoilage must be examined for the pre- 
sence of staphylococcal and clostridial toxins. 
Raw materials exposed toi warm, humid condi- 
tions thet induce fungal growth must be exam 
ined for the possible presence of mycotoxins, 
such es the aflatoxins. 
2.4.3. Residues 
Protein concentrates thet have been isolated or 
refined by means of solvent extraction should 
be enalysed for the possible presence of solvant 
residues and any products that may be formed, 
particularly by the use of reactive chlorinated 
hydrocarbons. In the avent thet any such resi- 
dues are present, toxicological data should be 
available to establish safe limits. Depending 
upon the nature of the raw materials, the me- 
dia, and the conditions of processing, analysis 
for the possible presence of impurities or conta- 
minants such as solvant residues, heavy metals, 
fluoride, etc., should precede any tox icological 
feeding studies. 
2.4.4. Nutritional Adequacy of Test Diet 
Il is essentiel to differentiate between nutrition- 
al inadequacy and appetite depressant effects, 
as well es toxicity, ail of which can suppress 
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growth. The basic diet to whlch test food Is 
added should itself be nutritionally adequate 
for normal growth and development of the 
animal species employed. The extent to which 
the test food may contrebute high levels of li- 
pid, carbohydrate, protein, minerais, or indi- 
gestibie material may create the need for ad- 
justments to balance out these factors be- 
tween the test and control diets. This applies 
to mon proteins, especially where the aminci 
acid content provided by the test material 
shouid be added to basal diet components in 
order to satisty nutritional requirements. 
Physical form of the diets is important. Experi- 
ence with laboratory rodents has shown that 
for a short-term study, i.e., a 3-month test, 
either a "synthetic" type diet, based on casein 
and starch, or "natural" diets, based on normal 
food ingredientes are satisfactory. However, 
for long-term chronic toxicity or carcinogeni- 
city studies, natural diets are essential. 
2.4.5 Highest Feasible Feeding Level of Test Food 
The nutritional and physical constraints piaced 
upon a food preclude the testing of large mul- 
tiples of potential-use levels, wich is accepted 
practice for the safety evaluation of food 
additives. Nevertheless, the highest dose level 
practicable shouid be included, keeping in mind 
that excessive amounts of high-quality foods 
may depress growth and feed efficiency. If 
feasible, graded levels of the test material 
shouid be reflected in the experimental de- 
sign, but it is not realistic to estabiish a dose- 
response curve. 
2.4.6 Cholee of Animal Species 
The rat is the preferred species. Mice are also 
used, but less is known of their nutritional 
requirements, and their site precludes ob- 
toining sufficient biood or urine for examine- 
tion. Among the non-rodent species, beagle 
doge, Rhesus monkeys, and miniature pigs 
have been used for short-term but not for 
chronic Iife-spen studies. 
2.4.7. Soloction of Animais, Animal Husbandry, 
Nature end Frequency of Observations 
These procgdures shouid be in compliance 
with Good Laboratory Prectice recommenda- 
tions. Technicel details for conducting indivi- 
duel tests mav be found in published interna- 
tional and national guidelines. 
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2.4.8. Nature of Studies to be Performed 
For screening purposes, nove) food products 
should be subjected at least to short-term toxi- 
cological tests in one rodent and one non-ro- 
dent species. They should also be examined for 
evidence of components with mutagenic po- 
tential by the use of a battery of mutagenicity 
tests in both prokaryotic and eukaryotic sys- 
tems, looking particularly for evidence of point 
mutations, chromosomal changes, and intefer- 
ence with DNA metabolism. The degree of no- 
velty of a potentially important food item 
(both source and method of production) should 
determine the need for definitive studies. A- 
mong these, reproduction and lactation studies 
are important. While they may not be indicated 
in the case of a fish or cereal protein concen- 
trate, such tests should be included in a proto- 
col for safety eveluation of single-cell protein. 
These tests should extend to at least two filial 
generations, and could be continued with 
teratology and dominant lethality studies. If 
necessary, the FI generation could be used for 
chronic toxicity and carcinogenecity studies. 
2.4.9 Statistical Analyses and lnterpretation of 
Findings 
In the interpretation of the responses to toxico- 
logical tests, the statistical significance of dif- 
ferences of responses between test and contre! 
groups plays an important role. Hence, the site 
of experimental groups as well as the quantita- 
tive rating of both objective and subjective 
observations are particularly relevant. 
However, whatever statistical probability is 
adopted as the basis for defining significance, 
the chance that a single group may deviate from 
the norm without actually indicating e biolo- 
gical aberration cannot be ignored. Judgment 
founded on experience of the investigator and 
prit performance of the particular strain and 
colony of animais must be given due weight. In- 
terpretation of experimental findings shouid 
take into account the quantitative relationship 
of the experimental test levels versus use condi- 
tions of the product under investigation, inter- 
species variations, the Iimited number and varie- 
ty of observations incorporated into the safety 
eveluation programme, and the relative size of 
the test and human populations. 
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INTRODUCTION 
Novel foods are defined as those that have flot been 
eaten before by the population for which they are 
intended, or et least flot in significant amounts. Similarly, 
nove) processes appliet! to traditional foods require 
examination, es do new varieties. After preclinical testing 
for possible toxic constituents, the features that require 
examination are nutritional value and components that 
may cause dietary intolerance. 
The tests outlined in PAG/UNU Revised Guideline 
No. 6, "Preclinical Testing of Novel Sources of Food" 
(1), should provide adequate information on the safety of 
e product before commencing any testing with human 
beings. Human testing, as outlined in the remainder of 
this Guideline, should only be carried out after e complete 
examination of the features defined in PAG/UNU 
Guideline 6. Although the toxicological tests outlined 
should be performed for very novel foods or nove) 
processes applied to traditional foods, there is e real 
danger of excessive and unnecessary experimentation with 
minor variations in' formulas using previously tested 
ingredients or processes. 
If animal tests reveal any toxicological problems, 
these should be resolved before the material is fed to 
humons. Examples are substances such es lectins 
(haemagglutinins), trypsin inhibitors, and cyanogenic 
glycosides. 
Other animal tests will reveal the available energy 
content of the food, digestibility and quality of the 
protein, and availability of minerais, thereby providing 
information on the nutritional value of the product that 
will complement the information from analysis of car- 
bohydrAtes, lipids, and fatty acid composition, proteins, 
and amino ecid composition as well as vitamins and 
minerais. 
Nutritional measurements on human beings are 
subject to such individual variation thay they rarely 
contribute as much useful information as the measure- 
ments of nutritional value in experimental animais. They 
may, however, be desirable in certain instances, such es 
when comparing the relative value of two sources, or 
substituting e nove) source for a traditional one. In such 
cases il is necessary to establish precisely what informa- 
tion is required and then to select from the tests described 
below those most likely to supply the answer to the 
appropriate questions. 
In general, il follows from firsi principles that any 
safe food that supplies significant dietary energy, protein, 
and other nutrients will be of value to the consumer. 
However, the acceptability of e food, or tolerance to that 
food once ingested, canne be foretold from animal 
experiments alone, and hence human testing is a pre- 
requ isite. 
CATEGORIES OF NOVEL FOODS 
Products that require full testing, both preclinically 
and clinically, are: 
1. Food sources flot previously consumed by 
human beings, or ai leasi not in the amounts 
proposed. 
2. Products previously accepted that have been 
subjected to such different processing condi- 
tions that questions can be raised regarding 
their nutritional or toxicological properties. 
3. In certain instances, new varieties of foods 
and foods newly introduced to a population, 
even though they have already been consumed 
safely in other areas. 
Il is assumed that the following information will be 
available in full detail before proceeding with human 
testing: 
1. Availability of supplies of the nove) food, 
including aspects of ils distribution and shelf- 
life. 
2. The mode of consumption, i.e., whether il is 
to be incorporated into other foods or dishes, 
used a.supplement, fed atone (as il may well 
be in the case of infant foods), or used as e 
substitute for traditional foods, and whether 
il is to be cooked after distribution. 
3. Full microbiological data pertaining to public 
health hazards. 
Particular cure should be taken to ensure that the ma- 
terial used in the tests is truly representative of the nove) 
food thet will ultimately be marketed. Whenever possible, 
the came large-sale industrial process Chat will be used to 
produce the nove) food for marketing should be used to 
produce the food used in testing, since the specifiation of 
food produced in e pilot plant may differ significantly from 
that produced commercially. Where there is an inherent risk 
of variability of the product - e.g., in yeast products - 
stringent batch control cher general production will be 
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necessary to ensure that the food as marketed does not dit 
fer from that tested. Single-cell protein preparations may 
need to be examined by suitable screening tests that should 
be applied after each process modification. It is also impor- 
tant to consider the form in which the food will be tested. 
Food that would normally be cooked prior to consumption 
should be treated in a similar manner before feeding or 
testing in vitro. 
NUTRITIONAL TESTING IN HUMAN SEINGS 
'.be approximate nutritional value may be deter- 
minad by chemical analysis. If the food is to be con- 
sumed processed or cooked, then the nutritional tests 
should be carried out on such cooked foods. For testing 
nutritional value in vivo, the food should be fed under 
the conditions it is expected to be consumed in practice, 
i.e., mixed with the rest of the diet in amounts likely to 
be used and not ai higher levels. Time and effort should 
not be devoted to measurements on the isolated food- 
stuff ai excessive levels when it is not intended to be 
consumed alone, and to measuring parameters such as 
conventional net protein utilization that have little rèle- 
vante. 
Methodologies for determining protein value 
through analytical procedures and experimental animal 
and human trials are given in the UNU Food and Nutri- 
tion Bulletin Supplement No. 4 on Nutritions/ Eva/uation 
of Protein Foods (2). Approximate protein value can be 
established by determination of essential amino acid 
composition and calculation of a protein score. If human 
feeding studies for this purpose are desired, procedures 
are available, although they are time-consuming, costly, 
and add littie to the information on protein value 
obtained from laboratory analysis and feeding exper- 
imental animais. It is, however, desirable to conduct a 
five- to ten-day nitrogen balance trial to measure the 
product's digestibility by human subjects. 
If the food is intended for infant feeding, selected 
anthropometric parameters can be measured over e period 
of ai least three months. These can be limited to weight 
and height increment, head and arm circumference, and 
triceps skinfold. Other possible parameters include serum 
and urinary urea, prealbumin, albumin, transferrin, 
cerulopiasmin, cholinesterase activity, aspartate amino- 
transferase (formely SGOT), hydroxyproline, creatinine- 
length index; and for vitamins, it may be desirable to 
measure the usuel enzyme-reactivation tests and other 
common nutritional indices. 
CRITERIA OF TOLERANCE 
It must be borne in mind that a significant per- 
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centage of individuals is intolerant to one or more 
traditional foods. It has been stated that there is no food 
that is wholly free of adverse effects in ai least an oc- 
casionai individual. Most individuals have ascertained by 
trial and error which foods cause them ill effects when 
these effects follow fairly rapidly after the ingestion of 
the offending food. Recent reports from the United King- 
dom suggest that about 30 per cent of the population sam- 
pled in some countries respond adversely to one or more 
foods, and up to 3/4 per cent avoid one of the major 
traditional foods widely consumed by the population as 
a whole (3). The frequency of allergic responses to milk 
protein atone is variously reported as up to 8 per cent (4), 
and allergies to chocolate, corn, légumes, eggs, citrus 
fruit, tomatoes, wheat, and pork are also very common 
(5). Allergic responses call for special consideration and 
can be specifically examined and characterized by the 
presence of antibodies. Gastrointestinal intolerance to 
ingested food will be indicated by loss of appetite, flatu- 
lence, undigested stool contents, diarrhoea, and abdominal 
pain. Cutaneous rashes are also quite common (6). 
PRELIMINARY ACCEPTABILITY AND TOLERANCE 
TESTS 
When nove) foods are developed, it is essential that 
their acceptability be evaluated in human subjects under 
controlled conditions before they are used in an un- 
supervised manner. A variety of adverse reactions may be 
observed in humans that are undetectable and unpredict- 
able in experimental and farm animais even with extensive 
testing. 
The most common symptoms to be looked for in 
human subjects are those of gastrointestinal intoierance. 
In addition, various allergic reactions may occur in some 
individuals after consumption of almost any common 
food, especially if it is a protein source. It is the fre- 
quency of such reactions that must be e9aluated rather 
thon their expected absence. Moreover, symptoms may 
be due to psychosomatic factors. 
Because of these factors, it is important to feed e 
control group simultaneously. Ideally, the trial is 
conducted so that individuals are randomly assigned to 
experimental and control groups, stratified by sex if 
necessary, in a double-blind cross-over design. Only after 
a Iow frequency of adverse symptoms is assured can 
additional trials be conducted without the necessaty of a 
control group. Once again, the inadvisability of high- 
level testing must be emphasized if the product is unlikely 
to be consumed et such levels; mistaken conclusions may 
be drawn from reactions et high-intake levais aven with 
traditional foods. 
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SUBJECTS 
In general, 25 to 50 human subjects can be siudied 
initially. Ail subjects should be in good health, as deter- 
mined by medical history, physical examination, and 
routine blood and urine tests. Individual medical histories 
should focus on a history of personal or family intoler- 
ance to specific foods and manifestations of aliergy, 
such as asthma, hay fever, and urticaria. However, no 
individuel should be excluded on this account, since il is 
essential to determine the prevalence of symptoms to the 
novel food in the general population for whom il is 
intended. The purpose of the study, the cooperation 
required, and potentiel risks involved should be explained 
fully to each subject. Protocols should be reviewed by 
the multidisciplinary group established by the institutions 
to evaluate such studies using humans as experimental 
subjects. In addition, subjects should sign appropriate 
consent forms. For subjects who are legally minors, 
written parental or guardian consent must be obtained. 
The actual numbers of individuals involved in the 
study will be a function of the preliminary data. True 
allergic responses will be characterized by antibody 
formation and will potentially require fewer participating 
individuals than in those cases where intolerance is a 
problem. In the latter case, this should be tested in a 
manner similar to that used for bacteriological sterility; 
that is to say, if any subjeci responds adversely, then the 
tests should be repeated on larger numbers of subjects 
to aster tain numbers Chat may be intolerant. So, while 
20 to 50 subjects may be an adequate number for general 
purposes if intolerance is revealed, this number may need 
to be increased. 
STUDY DESIGN 
Subjects should consume both the nove) and a 
controi food, preferably one that is already commercially 
available, in a double-blind cross-over study design. 
Subjects should be allowed complete freedom to consume 
their usual diet. Since this will vary and may include 
meals or foods that in themselves cause symptoms, il is 
essentiel that each subject keep a diary of ail significant 
departures from the usual in his or her daily diet and 
activities. These often prove of value in the retrospective 
interprétation of the results of a tolerance trial. 
An appropriate study period would be two four- 
week periods separated by a one-week interval. In the 
firsi four-week period, subjects ingest daily either a 
fixed amount of the controi or experimental material. 
After completing the initial phase, subjects 
will return to their regular diet without supplemente- 
tion. Thereatter, the second four-week period will be 
started, and subjects, unaware of the type of supple- 
ment they are taking, will begin inges-ting the second 
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protein. Administration of the material for five to six 
days each week for four weel s is adequate. Experience 
indicates that individuals not developing symptoms in the 
first 20 days are not likely to do so thereatter. 
METHOD OF ADMINISTRATION 
Any method of oral administration that facilitates 
e double-blind trial is acceptable. For example, the 
material can be incorporated into cookies, cakes, pudding, 
or other acceptable supplements to a usual diet if il can 
be introduced so that its presence cannoi be specifically 
identified. Novel foods in powder form can often be 
tested by allowing the subjects to mix them into bouillon 
or any of a variety of fruit juices according to individual 
preference, and they can vary their choice from day to 
day. In this case, however, there must be availabie a 
similar control material for which tolerance is already well 
established. Experienced nutritionists can usually find an 
acceptable method of administration. 
Ail subjects recruited should have the opportunity 
to taste the materials to be consumed before making a 
commitment to the trial. If this is flot done, a number of 
subjects are likely to confound the trial by dropping out 
in the first few days because they do not like the teste, 
texture, smell, or some other aspect of the substances 
offered. 
LEVEL OF FEEDING 
Toeerance studies should be designed taking into 
account the intended use of the substance. For example, 
yeast es e vitamin supplement may be consumed ai less 
than 5 grams daily, as a functional food additive rarely 
more than 10 grams, but as a significant protein sup- 
plement, the amount might be 30 grams or more, 
providing il does not supply more than 2 grams of 
nucleic acid. If the amouni intended for testing is more 
than 15 to 20 grams per day, il should be divided into 
two or more feedings per day. If a supplement is intended 
to be added to a traditional staple like breed or a rite 
dish, then il should be given daily or even more fre- 
quently, in relatively large amounts, following normal 
dietary practice so that the experimental material is fed 
et the upper intended limit of use, which may involve 
daily administration of 30 grams or higher. 
For e totally new food source il may be more 
prudent to conduct a pilot trial with a smaller number of 
subjects ai e lower level. Materials intended only as 
minor additives to a mixed diet may be tested ai levels 
as low as 5 to 15 gran-ms daily. When evaluating the data, 
two contrary effects may be noted: intolerance to which 
the subject soon becomes adapted, and boredom from 
eating the saure food over e prolonged period. The former 
(es in flatulence) can be examined by introducing the 
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food in small and increasing amounts over a few days. 
The latter will always be true even for attractive 
traditional foods if eaten too frequently. 
LEVEL OF DIETARY ENERGY INTAKE 
The level of dietary energy intake should be suf- 
ficient to maintain constant weight in adults or adequate 
weight gain in children. 
OBSERVATIONS TO SE MADE 
Before subjects begin the feeding trial, initial blood 
tests are required. These should include haemoglobin or 
haematocrit, white blood count, and a peripheral blood 
smear to determine the percentage of the white blood tell 
components. In addition,serum electrolytes, blood urea 
nitrogen, creatinine, and serum uric acid should be 
obtained. Tests of liver function should be included; 
i.e., albumin globulin, bilirubin, aspartate aminotransferase 
(SGOT), alanine aminotransferase (SGPT). Serum 
calcium and phosphorus should also be determined. A 
urine sampie should be obtained for complete analysis of 
tells, protein, and pH. 
These blood and urine tests should be repeated et 
the end of the study or sooner in subjects dropped from 
studies because of adverse reactions. Il is important to 
ascertain if any of these biochemical parameters change 
during the acceptability study. Examination of the 
serum immunoglobulin levels is necessary in individuals 
with possible allergic reactions. 
Further, to assure that the nove) food is not as- 
sociated with unpleasant or adverse reactions, all par- 
ticipants in the study should be asked to keep a diary 
as noted above that will note changes in mood, appetite, 
sleep patterns, libido, and other subjective reactions. 
UNNECESSARY TESTING 
Much lime and effort has been devoted in the part 
to measuring such parameters as protein quality (by PER 
or NPU) in human beings. This is not necessery for two 
reasons: 
1. Results obtained in closely controlled labore- 
tory tests are often not repeatable under field 
conditions. This would indicate that such 
parameters are unimportant under normal, 
free-living (field) conditions. 
Most such measurements have been cerried 
out on the food atone or on protein isolates, 
whereas il will be consumed mixed together 
with other foods. Consequently, the protein 
quality of the food alone is not of any interest 
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For example, a protein source completely 
deficient in one essential amino acid might 
well be rejected as the result of such tests, 
whereas if the missing aminci acid is not 
limiting in the mixed diet, theh that protein 
may make a valuable contribution to the dies. 
GENERAL CONSIDERATIONS 
Il follows from first principles that any safe food 
that supplies additional energy, protein, and other nu- 
trients will be of value even if it is not possible to dem- 
onstrate such bene fit in the trials. While il may be neces- 
sary in order to convince policy makers and governments 
to demonstrate the benefits of the nove) food (in which 
case growth, nitrogen balance, skinfold increases, etc. 
may need to be measured and reported), il is not neces- 
sary for the nutritionist. While he would often like to 
quantify the benefits of the supplement, such mea- 
surements are open to enormous individual variation and 
rarely have any real meaning. The only instances where 
such measurements may be of value are when different 
sources of nutrients are being compared, and even then 
the variability of the findings usually vitiates the results. 
Economic and palatability considerations frequently 
outweigh all such technical detail of nutrient differences_ 
For example, while weight gain is the best measure 
of the value of a supplementary food, such measures 
require prolonged periods of testing (several months) and 
show the most marked results in children who were 
previously poorly nourished. Such methods cannot be 
applied to adults. Any supplement that provides ad- 
ditional energy and nutrients will be of value when the 
dies has been poor, and testing the precise effects of such 
supplements is often quite superfluous and costly. 
Finally, once the use of a product has commenced, 
il is advisable to have a mechanism by which any adverse 
reactions may be monitored in order that corrective 
change may be introduced. 
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PAG/UNU GUIDELINE No. 12: THE PRODUCTION OF SINGLE-CELL 
PROTEIN FOR HUMAN CONSUMPTION 
The following is presented to supplement PAG/UNU Guidelines 6 and 7 as a generai guide for producers on 
processes for, and products from, single-celi protein ($CP). Because of the large number of potentiel organisms and 
processes, a complete description of any individuel process is beyond the scope of this Guideline. 
1. INTRODUCTION 
SCP is defined here as a biomass of yeasts or other 
fungi, bacteria, and algae to be produced and/or 
processed as food for human consumption. Such food 
in addition to protein has a significant caloric and 
other nutrient content, e.g., vitamins. The nutritive 
value of the protein component is of particular 
importance if the product is to be used as a protein 
supplement 
The traditional concept of "gond manufacturing prac- 
tice- should apply in the senne that it is currently 
used in the food industry. Plants and equipment 
should be of sanitary design, and special tare should 
be exercised in ail aspects of processing, including 
raw material selection, quality control, sanitation, 
handiing, and packaging. 
2. TYPES OF ORGANISMS 
Various types of organisms have been considered as 
potentiel sources of SCP and appear to be capable of 
meeting the criteria established in this Guideline. It 
is preferable to select an organism of a species known 
not to produce pathogenic or toxic variants. 
To comply with non-pathogenicity requirements, the 
final product should contain no living tells derived 
from the fermentation process. Each individuel strain 
eventually should be evaluated under the exact condi- 
tion proposed for industriel production. 
3. PROCESSES 
3.1 Raw Materials 
Patent ai carbon sources include carbohydrate- 
containing materials (molasses, various sources of 
starch or other polysaccharides, cellulose, whey, 
sulfite liquor, etc.), various classes of hydrocar- 
bons (methane and longer-chain normal alkanes), 
alcohols (methanol and ethanol), organic acids, 
and carbon dioxide. In view of the variety of 
carbon substrates, attention must be directed to 
the composition of the media from the stand- 
point of the possible presence of chemical 
components (e.g., polycyclic aromatic hydro- 
carbons from petroleum) that are regarded as 
health hazards. In addition to the carbon 
substrate, other material: invoived in the 
process, include sources of nitrogen, buffer salts, 
minerais, vitamins, air or oxygen, and many 
contain chemicals such as anti-foam agents. 
detergents, and flocculants. No material should 
be introduced into the process that cannot later 
be removed from the SCP product if necessary 
to meet safety requirements. 
3.2 Process Variables 
Operating variables of fermentation, such as tem- 
perature, air or oxygen supply, pH, tell growth 
rate, and tell concentration must be carefully 
controlled to ensure the required product quality 
and uniformity. The operations following tell 
production should aiso be monitored to ensure 
the required product quality and uniformity. In 
generai, this will necessitate careful and conti- 
nuous monitoring throughout the course of prod- 
uction and an understanding of the influence 
of these variables on the composition of the 
product. 
3.3 Quelity Control 
In addition to quality control procedures 
associated with factors listed under point 5 
(nutritional evaluation), careful attention should 
be paid to the maintenance of the integrity of 
the original strain of the organism. An appropri- 
ate series of microbiological and biochemical tests 
should be worked out both to demonstrate the 
stability of the organism and the absence of 
undesirable contaminants. 
4. SAFETY EVALUATION 
The procedure for safety evaluation is outlined In 
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PAG/UNU Revised Guideline No. 6, "Preclinical 
Testing of Novel Sources of Food." Following this 
testinç, thorough clinicat evaluation is particularly 
necessary because of effects such as allergenicity, 
uricogenesis, subjective responses, and other reactions 
thet can be determinend only in humans. Thesetests 
area outlined in PAG/UNU Revised Guideline No. 7, 
"Human Testing of Novel Foods."' 
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6.3 Lipids 
Total lipids should be analysed. If lipid content 
is greater than one per cent, the fatty acid profile 
should be determined. Triglycerides, phospholi- 
pids, and steroid values need to be expressed. 
6.4 Ash 
6. NUTRITIONAL EVALUATION 
The nutrition quality of the SCP is to be determined 
for protein and for other nutrients, as recommended 
in the above-mentioned PAG/UNU Guidelines. 
6. COMPOSITION 
This should be analysed for minerais of biologi- 
cal importance such as iron, iodine, alkali, alka- 
line, earth, and heavy metals. The bioavailability 
of the minerais of nutritional importance can be 
determined only by measurements in humas 
beings. 
6.1 Pro tein 
Crude protein is total N x 6.25. Total N includes 
non-protein N and non-amino acid N, such as 
nucleic acid, urea, amines, and ammonia. The N 
conversion factor for true protein depends upon 
amino acid composition. Because of these varia- 
bles, true protein should be determined by amino 
acid analysis. As an approximation, corrected 
protein N can be calculated by subtracting 1.4 x 
purine N from crude protein N. 
6.2 Nucleic Acids 
There is a limitation to the amount of nucleic 
acide that should be introduced into human 
diets, because nucleic acid purines are excreted 
by man principally as uric acid. In susceptible 
individuels elevated levels of serum uric acid 
increase the risk of gout, and increased urinary 
concentration of uric acid may result in the for- 
mation of uric acid calculi (1). 
The currenfiy available information (2,3) 
suggests that there should be sot more than two 
grams of nucleic acid per day introduced into the 
diet by SCP for aduits, and correspondingly leu 
for children, depending on their weight. Because 
of variations in the nucleic acid content of the 
biomass of different species, the nucleic acid con- 
tent can be most usefully expressed as per cent 
of product 
Forthcoming 
6.5 Dietary Fibre 
Non-digestible materials should be analysed and 
taken into account in the determination of 
energy value of SCP. The effect of any such 
materials on the availability of essentiel nutrients 
from the remainder of the diet should be deter- 
mined. 
TABLE 1. Suggested Limits for Viable and 
Contaminating Micro-organisms 
M icro-organism Number per Gram 
Viable bacteria 100,000 




1 per 50 g 
Staphy/ococcus aureus 1 
Clostridia, total 1,000 
Clostridia perfringens 100 
Lancefield Group D Streptococci 10,000 
6.6 Solvant Rosidues 
These should not exceed those compatible with 
good manufacturing practice. Methods of analy- 
sis are given in the 14th Report of Joint FAO/ 
WHO Expert Committee on Food Additives, 
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FAO Nutrition Meetings Report Series No. 48, 
and accompanying monographs, including those 
for determining residues in foods. 
7. SANITARY ANALYSIS 
The microbial standardsshould comply with Table 1. 
Food and Nutr/rlon Bulletin, Vol. 5. No. 1 
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PAG/UNU GUIDELINE No. 15: NUTRITIONAL AND SAFETY ASPECTS 
OF PROTE IN SOURCES FOR ANIMAL FEEDING 
1. PROBLEMS AND ISSUES 
The need to expand the world supply of protein for 
human food and animal feed has been well documen- 
ted. The basic problems are: 
Guideline No. 7). - These Guidelines were stimulated 
originally by the potential direct use by human beings 
of microbiel biomass grown, in some cases, on uncon- 
ventional substrates such as hydrocarbons and simple 
alcohols. 
a) Increasing woridwide demand for protein. 
b) An immediate need to upgrade proteins in many 
areas of the world. 
c) The demand'created by both agriculture and in- 
dustry to modify existing protein supplies and 
produce new sources and forms of protein. 
d) Demands by many governments to evolve objec- 
tive regulations controlling the quality and safety 
of modified and novel protein sources, such regu- 
lations to be capable of harmonization at the in- 
ternational level to the greatest possible extent, 
e) The need to allow unrestricted and unimpeded 
international export and import of such pro- 
ducts, which will require international similarity 
of national regulations. 
These developments have several implications for the 
future. They imply a possible revolution in animal 
and human feeding, as people will consume meat, 
milk and eggs from animais receiving new forets of 
protein in their feed rations. Before very long, increas- 
ing numbers of human beings may receive such pro- 
tein foods es direct components of their diet. Thus, 
there is a need to ensure that the new proteins will 
have e beneficial effect on the nutrition and health of 
intermediate and final consumers. 
After these Guidelines were initially written, a series 
of singlecell proteins were evaluated using the cri- 
teria as originally defined. Their safety, utility and 
efficiency have been cleerly demonstrated. The 
products have been manufactured and no hazards 
were detected in the original experimental work or 
in subséquent commercialisation of these products. 
Experience has shown that it is necessary to establish 
acceptable criteria for determining the nutritive value 
and safety of protein materials in relation to their use 
in the rations of the particular animal species con- 
cerned, and to consider also the public health 
implications resulting from the use of the same 
animais for human feedirg. 
The PAG/UNU has well-developed Guidelines for the 
preclinical testing of nove? food in laboratory animais 
(PAG/UNU Guideline No. 6), and for their clinical - 
avaluation in human subjects (PAG/UNU Revised 
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The concepts expressed in PAG/UNU Revised Guide- 
line No. 6 are also relevant to an animal feeding situa- 
tion, but the need to use laboratory animais as 
models for testing new food components is removed 
because of the ability to test directly in the "targes 
species" -the domestic and farm animais for which 
they are intended. Such experiments are of equal, if 
not greater, importance than those obtained from 
conventional experimental animais. However, this 
does not imply that the latter, which are the biologi- 
cal tools of the toxicologist and nutritionist, cannot 
provide information relative to the consumption of 
animal products by humans. 
2. THE NEED FOR GUIDELINES 
The question arises as to the necessity or usefulness 
of establishing guidelines for testing protein sources 
proposed for animal feeds in addition to those alrea- 
dy established for preclinical evaluation of nove) 
foods for human consumption. The guidelines have 
been useful to industriel producers of single-cell 
proteins, e.g., selected yeasts, bacteria, etc., es the 
companies required an internetionally and mutually 
agreed upon standard by which both they and govern- 
ments could Bauge the quality, uniformity, nutritive 
value, and safety of their products. The need to main 
tain this is still apparent, as is the need to evaluate 
more conventional feed protein sources produced 
with the eid of extensive processing systems. 
The material to be evaluated initially cannot be de- 
rived from full-:cale plant production; testing and 
product acceptance must therefore involve products 
from pilot plants. Confirmation thet the pilot-scale 
product is similar to the final product is also 
requ i red. 
Many factors must be considered for prior approval 
of protein sources, including the quality of the raw 
materials, the aceeptability of the critical processing 
techniques affecting nutritive value, satety, purity, 
and uniformity of the ultimate commercial 
Forthcoming 
68 PAG/UNU Guwdei ne No 15 
output compared with the pilot plant product pre- 
viously evaluated and approved. 
In the case of SCP products, the genetic stability of 
the micro-organism subjected to continuous fermen- 
tation must also be considered. This requires careful 
development of physical, chemical, and microbiolo- 
gical specifications as well as nutritional and toxicolo- 
gical measurements appropriate for the target species. 
The extent to which it is necessary to repeat toxicolo- 
gical and nutritional studies on micro-organisms that 
have been genetically engineered will depend on the 
nature of specificity of the DNA interchange between 
the vector and the host and an understanding of the 
relative safety of the original vector donor. 
3. THE PURPOSE OF GUIDELINES 
As stated in PAG/UNU Revised Guideline No. 6, it 
must be understood that a published guideline does 
not constitute a compendium of mandatory tests 
that, unless completely and successfully satisfied, 
would preclude acceptance of any new food compo- 
nent. Indeed, with the accumulation of experience in 
routine testing of these products and their feeding 
to livestock under practical conditions, it seems likely 
that more informative and possibly more routine test 
procedures will emerge that will permit improved 
testing efficiency and economy. It is recognised that 
toxicologists and nutritionists experienced in these 
matters should have the prerogative to decide on the 
extent and design of experimental protocols. 
For the guidante of those who may lack the necessa- 
ry resources in these highly specialised disciplines, it 
is considered useful to suggest procedures to support 
acceptable conclusions as to both functionai utility 
and safety of protein sources. Many aspects of the 
criteria described in PAG/UNU Revised Guideline No. 
6 are applicable to proteins intended for animal feed- 
ing; particularly relevant are the sections dealing 
with chemical, physical, and biologicel evaluatlons. 
However, the criteria for the prediction of protein 
quality of foods used in human nutrition, e.g., bio- 
assays for protein efficiency ratio, net protein utilisa- 
tion and biological value, while of interest, are not 
directly applicable to animal nutrition. This explains 
the importance of establishing the quality and safety 
of feed ingredients for nourishment and productivity 
directly in the target species. Products intended for 
incorporation into animal feeds may not require as 
extensive testing as that suggested for human foods, 
but foods derived from animal sources must be consid- 
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ered from the viewpoint of the possible presence of 
residues in meat, milk or eggs transmitted from ani- 
mal feeds. 
4. TERMS OF THE GUIDELINE 
When reviewing thé éléments of this Guideline, ref 
erence should first be made to the introductory pages 
of PAG/UNU Revised Guideline No. 6, particularly 
those dealing with the categories of information 
needed (1.1- 1.5) and evaluation procedures (2.1- 
2.4). With respect to ingredients intended for animal 
feed purposes, the Guideline covers aspects specifical- 
ly applicable to the feed requirements of the species 
concerned as well as aspects applicable to foods de- 
rived from these animais and intended for human use. 
With respect to the species involved, the Guideline 
provides for the évaluation of the quality and effi- 
ciency of the protein for maintenance, growth and 
reproduction, its safety for the target species, and its 
effect on productivity from the economic standpoint. 
With respect to foods derived from these animais, 
consideration of acceptability in terms of flavour, 
colour, texture, etc., would have been taken into 
account before marketing any such product. Safety 
for humans would involve the possibility of contami- 
nants or residues arising from processing or source 
materials, e.g., substrate or media employed in the 
case of SCP. In generai, protein molecules themselves 
would be unlikely to present a hazard. The quality 
and safety of food from animais fed unconventional 
protein shouid be predictable from the nutritional 
and toxicological studies of the protein in the animais 
f ed. 
Because of the impracticality of identifying, by 
means of animal feeding studies, the minute traces 
of residues or contaminants that might be transmitted 
from the feed into meat, milk or eggs, detection 
of any such substances that might be suspected to be 
present must depend on highly sensitive chemical 
analytical procedures. The feeding of meat/fat from 
feed animais to laboratory animais to assess toxicity 
has been suggested as a means of gaining en insight 
into the residues of animal products. Experience 
has shown that, although such protocols might iden- 
tify very potent toxic or pharmacologically active 
substances, in ail other cases the dilution factors 
involved in the passage of these supplements through 
the food animais are so vast as to make these kinds of 
study relatively meaningless. 
In view of the fact that some types of protein sources 
may be produced in the form of microbial biomass 
under industrially controlled conditions using agricul- 
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tural or industrial waste. including both human 
and animal sewage, special attention must be directed 
toward ensuring the absence of pathogenic organisms 
and metabolites (PAG/UNU Guideline No. 12), as 
well as toxic residues of pesticides or drugs. In the 
case of inocula for SCP production from any sub- 
strate, the micro-organisms selected should be non- 
pathogenic, notwithstanding the tact that the fermen- 
tation process need flot involve the use of pure 
cultures grown aseptically. 
Alter the processing conditions have been established 
to ensure uniform quality, safety, and nutritive value 
of the final product, chemical criteria should be 
determined, as suggested in Table 1. 
Sensitive, quantitative analytical procedures must 
be used to determine the levels of any undesirable 
residues that could arise from the source or media 
from which the proteins are derived, or from solvents 
and other agents employed in any stage of proceuing. 
For in-plant control, the methods of examination and 
analysis should be capable of giving valid, reproduc- 
ible results. 
5. NUTRITIONAL AND SAFETY EVALUATION 
The nutritional value of novel proteins for animal 
feeding should be determined in the species for which 
its use is intended and et far es potable under simula- 
ted practical conditions. In experimental diets con- 
ventionally employed for evaluation in rats, the test 
protein is incorporated as the sole source of nitrogen. 
Since new protein sources would be used in animal 
feed es a sifpplement or partial replacement of soy- 
bean, fish meat, or other protein component of the 
total ration, test diets should reflect likely local, 
prectical rations. Oecasionally it may be necessary to 
affect e total protein replacement, but supra-high 
protein levels resulting from high test product incor- 
poration should be evoided, es there could introduce 
irrelevant effects of no significance in the evaluation 
of safety. 
To achieve the best utilization of protein sources used 
in animal feeds, consideration may be given to supple- 
mentation with synthetic amino acids essential for 
the species in question; e.g., lysine for pigs and me- 
thionine for poultry. 
in the design of experimental rations for nutritional 
or toxicological evaluation, cire must be exercised 
to ensure that normal dietary requirements for the 
species in question are satisfied in order not to con- 
fuse nutritional affects with toxic effects. Dietary defi- 
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ciencies or imbalance may yield apparent toxicologi- 
cal symptoms that are not due to the test material as 
such, e.g., minerai imbalance causing nephrocalcinosis 
in rats, or impaired growth response. 
TABLE 1. Suggested Criteria for Detining Protein 
Sources to be Used for Animal Feeding 
For API Novel Protein (Dry Weight Basis): 
Total nitrogen, full amino acid profile, nucteic acid, and 
other non-amino components 
Total lipid, fatty acid profile, glycerols, phospholipids 
Carbohydrates 
Fibre content 
Ash, inorganic components 
Trace minerai components (beneficial: Co, Fe, Zn, Mn, Cu) 
(harmful- As, Hg, Pb, Cd) 
Vitamins 
Gross and available energy values 
Residual substrates, processing aids 
Residual harmful components (e.g., benzo(a)pyrene, 
nitrosamines) 
Availability of nutrients should be defined where possible 
' If specific carcinopenic polynuclear aromatics are found, this might naed additional testing 
6. TEST SPECIES 
In considering the test species for toxicological test- 
ing, there are two major points of interest: first, 
human beings will consume the animais fed the pro- 
tain, and second, the health and well-being of the 
recipient animal. Regarding the former, there is the 
ideal situation of identifying aIl the constituents of 
animal products so as to be assured of their safety. 
However, the technicel difficulties manlfest for the 
products under consideration make it necessary to 
adopt indirect moine. Therefore, the types of studies 
that are relevant to establish prectinicel safety are also 
suited to this context (PAG/UNU Revised Guideline 
No. 6). Therefore, es there lis en intermediete hosi 
whose can also be examined in this type 
of study, the clessical laboratory animal studies can 
be leu extensive unless the data obteined suggest 
that there is such e need. When considering thechoice 
of animais, a rodent species (preferably the rat). and 
a non-rodent mammal (which may be one of the targes 
species) are generally employed. As there Is emphasls 
on biologial quality es well es toxicological safety, 
the feeding studies with the target species (e.g., 
chiokens, pigs, fish, calves, etc.) are of considérable 
value. 
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7. PROTOCOL FOR EXPERIMENTATION 
7.1 Laboratory Animais 
Reference should be made to PAG/UNU Revised 
Guideline No. 6, Section 2.4 for an outline of the 
basic method for safety evaluation of novel foods 
in rats. The studies should be conducted with 
groups of experimental animais of sufficient size 
to yield statistically significant resuits. Physical 
inspection of the animais, including observations 
of weight changes, feed conversion, gross and 
histopathology, haemocytology, and blood and 
urine chemistry should be conducted ai appro- 
priate intervals. 
Reproduction studies in a suitable species are 
considered essential, extending for ar Ieast two 
generations. 
When there is evidence to suggest the need to do 
long-term studies to establish the absence of po- 
tentiai carcinogens or chronic toxicity due to 
cumulative effects, these should be done in ai 
feast two laboratory species. 
7.2 Target Species 
The ultimate tests of the nutritionai value for 
animal feeds are the practical trials in which 
growth, feed efficiency, reproduction, health, 
survival, and productivity are the bases for eva- 
luation. Short-term feeding studios are only 
minimal pre-requisites for the introduction of 
protein sources. Because of the short duration 
of such tests relative to the total lite span, 
it is not possible in these tests to observe 
evidence of long-term (chronic) or cumulative 
effects. Thus, studies for reproductive perfor- 
mance and for carcinogenicity are required where 
substrates or processing adjuncts suggest the 
need. If the proposed feed ingredient is to be 
incorporated in the ration of breeding animais, 
the appropriate reproductive data should be 
collected. Where the target species serves for the 
non-rodent mammal in toxicological studies, 
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biological data should be similer to those gath- 
ered from the rat. 
8. REGULATORY ASPECTS 
Information concerning certain proprietary process de- 
tails may be required to provide assurance of safety and 
to ensure adequate quality controi as well as uniformi- 
ty of the final produci. Examples of process deuils thit 
should be reported in the case of single-cell protein 
production are the nature and properties of the 
micro-organism, the qualitative composition of the 
substrate raw materials employed, including major 
nutrient supplements, and the agents used for spe- 
cial purposes, such as defoamers, emulsion breakers, 
etc. General processing conditions, such es fermenta- 
tion method, extraction processes, concentration pro- 
cedures, drying methods, etc., should be described to 
the extent needed. Similar criteria for other protein 
sources will need to be described for each product. 
Conformity of the commercial product with the regis- 
tered product should be based on appropriate sem 
pling of products in the manufacturing plant or in 
commercial channels. The chemical and biological 
testing procedures, therefore, will include general 
methods applicable to ail protein sources and feed in 
general, and to methods selected, especially to relate 
to the registered product. Certain data to establish 
criteria of identity should be included in label infor- 
mation. 
Approval of a protein source would require state- 
ments within the submission detailing nutritional 
quality, and ail safety criteria as outlined within this 
document. Changes in processing that might affect 
these features must be reported before the changes 
are effected. 
Chemical, nutritional, and microbiological quality 
characteristics referred to in this document may be 
found in PAG/UNU Revised Guideline Nos. 6, 7, 
and 12. Requirements for additional or improved 
analytical methods for evaluating novel proteins will 
be referred to appropriate committees of the Interna- 
tional Union of Pure and Applied Chemisty (IUPAC). 
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MEMORANDUM ON THE TESTING OF NOVEZ FOODS 
INTRODUCTION 
This Memorandum has been produced for the guidance of companies 
interested in developing or marketing nove! foods, including foods produced 
by nove! processes, in the United Kingdom. 
Part 1 provides a definition of novel fonds and sets out voluntary, pre- 
marketing procedures for companies a. to notify the Ministry of Agriculture, 
Fisheries and Food of new food products which appear, to fall within the 
definition, and h. when appropriate, to seek Ministerial clearance of nove! 
f oods. 
Part 2 provides Guidelines, which have been elaborated by the Advisory 
Cornmittee on Irradiated and Novel Foods, on the range of testing which, 
depending on the degree of novelty and the nature of the product, might have 
to be carrier! out satisfactorily before Ministerial clearance of a novel food 
could be given. 
1 
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PART 1: THE VOLUNTARY NOTIFICATION AND 
MINISTERIAL CLEARANCE PROCEDURES 
BACKGROUND 
Legislative position 
1 . In England aud Wales, the Food and Drugs Act 1955 prescribes offences 
in respect of the sale of any food intended for human consumption - 
a. which, by the addition of any substance as an ingredient in the 
preparation of the food, the abstraction of any constituent from the 
food or the subjection of the food to any other process or treatment, 
lias becs rendered injurious to health (Section 1); 
h. which is not of the nature, substance or quality demanded by 
the porchaser (Section 2); 
C. whase labelling falsely describes the food or is calculated to 
mislead as to its nature, substance or quality (Section 6); 
d. which is unfit for human consomption (Section 8). 
2. Ministers have no statutory authority to intervene in the technical 
development of a food. They may however make Regulations, in respect of 
food intended for sale for human consomption, to control its composition 
and the use of any process or treatment in its préparation (Section 4). In this 
connection, Ministers are empowered to obtain by Order details of the con- 
sumption and use of any substance employed in the preparation of the food 
and deuils of investigations carried out on the substance (Section 5). 
3. Parallel provisions exist in the separate Food and Drugs Acts for 
Scotland and Northern Ireland. 
Development of the procedures 
4. As a result of an understanding reached with the Ministry of Agricul- 
ture, Fisheries and Food (MAFF) in 1980, the then Food and Drink 
Industries Council (FDIC) invited its member associations to recommend 
their member companies to notify MAFF before marketing a novel food so 
that the nutritional and safety aspects of the food might first be evaluated, in 
strict confidence, by independent experts. This understanding reflected a 
recommendvtion of the Food Standards Committee in its "Report on Novel 
Protein Fonds" (published in 1974). 
5. It is now hoped Chat ail companies responsible for developing or 
marketing novel foods will participate in these arrangements, which have 
since been modified as described below. The considérable benefits to be 
derived from improvements in food production are fully recognised and it 
is emphasised that, in the operation of these voluntary procedures the aim 
will be to ensure that novelty per se is not disadvantaged. 
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The Advisory Committee on Irradiated and Novel Foods 
6. Since the understanding was reached between MAFF and the FDIC, 
Ministers have appointed the Advisory Comrnittee on Irradiated and Novel 
Foods (ACINF): "To advise Health and Agriculture Ministers of Great 
Britain and the Head of the Department of Health and Social Services for 
Northern Ireland on any matters relating to the irradiation of food or to the 
manufacture of novel foods or foods produced from nove) processes, having 
regard where appropriate to the views of relevant expert bodies." These 
other bodies include the Panel on Novel Foods, tire Cominittee on Toxicity 
of Chemicals in Food, Consumer Products and the Environment, and the 
Standing Panel on Hazards from Microbial Contamination of Food. As 
part of its remit, the ACINF lias been given responsibility for evaluating 
applications for Ministerial clearance of novel foods. The ACINF's member- 
ship and secretariat are given in the Appendix. 
THE VOLUNTARY PROCEDURES 
Definition of a nove) food 
7. Foi the purpose of the voluntary procedures, the following definition 
has been adopted - 
"Nove) foods aie Foods or food ingredients produced from raw 
material, which has not hitherto been used for human consumption or 
which lias been consumed in only small amounts, or produced by riew 
or savQrvly modified processes not previously used in the production of 
food". rryt 'nsi ve1 v 
This definition includes novel Foods hitherto consurned in only small amounts 
in the UK in case those foods might give rise to adverse effects il consumed in 
large, quantities. As to severe modifications to existing processes, these are, 
like new processes, potentially capable of bringing about changes of toxico- 
logical or nutritional Qnents extracted from conventional 
foods by traditional processestare riot coflsidered to be novel foods. 
Notifications 
1 
8. Any company proposing fo develop a new food product, or to market 
an imported one, which appears to fait within the terms of the definition in 
paragraph 7 above, is requested to notify - 
Food Science Division 
Ministry of Agriculture, Fisheries and Food 
Great Westminster House 
Horseferry Road 
LONDON SWIP2AE 
Ali information will be treated in confidence. 
9. In practice, il is expected that in most cases the nove) features of the 
4 
WA FT 
product will flot be such as to raise questions of safety to the consumer or of 
nutritional adequacy. In these cases formai Ministerial clearance would be 
inappropriate and the company will be advised accordingly. Nevertheless, the 
company would stil) need to consider whether the product had been tested 
adequately to meet the provisions of the Food and Drugs Acts and subordinate 
legislation. 
10. In other cases, the company will [le invited to apply for Ministerial 
clearance of the nove) food and will be given an indication of the extent of 
the data to be submitted and of the likely duration of the evaluation. It will 
lie for the company to decide whether or not to apply. 
Évaluation and Ministerial clearance 
11. When a formai application is made, it will be referred to the ACINF 
who, alter seeking the views of other expert bodies as appropriate (see 
paragraph 6 above). will evaluate the information provided and any additional 
data it might request. The ACINF will advise Ministers of its conclusions but 
this advice will flot be binding on Ministers, who will be responsible for 
deciding whether or flot clearance should be given. 
12. The views of Ministers will be notified to the company in writing. It is 
emphasised tlrat Ministerial clearance of a novel food will flot absolve a 




PART 2: GUIDELINES FOR THE TESTING OF NOVEL FOODS 
GENERAL CONSIDERATIONS 
Introduction 
1. As the tests appropriate to a particular nove) food will depend on ifs 
source, composition, processing and proposed level in the diet, it will be for 
the company, in the light of its experience and knowledge of the product, to 
make the initial assessment of which tests are needed. The tests detailed in 
the following patagraphs will be necessary for foods of extrerne novelty 
of eaw rnaterial or process; exceptionally, additional testing may be needed. 
However, for many nove) foods it is expected that some of the suggested tests 
may, subject to sound scientific justification, be omitted. In all tests, due 
accourt should be taken of any further processing to which the nove) food 
will be subjected and of any changes which might occur on storage. lt is 
desirable Chat, whenever possible, the results of the tests carried out on the 
nove) food should be published in the scientific literature. 
Background information 
2. It will always be necessary to detail the nove) food's nature, its 
production process and its potential market. This information will be of 
particular value for assessing the extent of the nutritional and toxicological 
data required. For example, for some nove) foods (such as those unlikely to 
play a significant rote in the diet) extensive nutritional evaluation is unlikely 
to be required; for others an acceptable presumption of safety may follow 
from specific chemical studies; and for a few an exhaustive evaluation may 
be necessary before the product can be considered safe. 
3. The source of the nove) food or.its production process may indicate 
potential problems. Novel foods produced from plant material may need to 
be examined for the presence of particular natural toxins or antinutritional 
factors. Novel fats and oils should be examined for is Tatty aci d g 
erucic acid). Novel foods produced from marine products may need 
examination for heavy metals and bio-toxins. Production processes involving 
microorganisms or permitting microbial contamination may indicate the need 
for examination for toxins or pathogenic microbes. Chemical processing or 
harsh physical processing may necessitate examination for toxic products or 
1 
4. The structure and site of tue market for the nove) food and its average 
intake should be estimated on the basic of its potential use las 1ndicated by its 
properties) and the marketing limitations imposed by the projected scale of 
the production facilities. In addition, groups in the population which might 
have a much higher intake than the average should be identified and the 
maximum levels of consumption estimated. As far as possible, any existing 
foods in the diet expected to be displaced by the nove) food should also be 
identified. This information should enable the test data on-the nove) food to 
significant damage to nutrients. 
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be seen in perspective (for example the nutritional aspects of the nove) food 
would have greater significance if it were likely to replace an existing major 
dietary nutrient source) and any disadvantages in replacing existing foods 
weighed against any possible advantages. 
Specifications 
5. An application for clearance of the nove) food should include the 
product specification- This will facilitate assessment of the limits within 
which the composition of the product is controlled. The specification should 
be accompanied by details of product variability and of the analytical 
rnethods and sampling protocols used to check the specification. Il the 
nove) food is so complex that a comprehensive product specification is 
impracticable (as it might be for a microbial protein), a process specification 
may be used to augment the product specification. 
6. If tlre application relates to a novel food produced on a pilot scale 
(which seems likely to be the usual situation), the company will have to 
demonstrate that when produced in a larger scale plant the food will be 
nutritionally and toxicologically consistent in all respects with that cleared 
and that each batch will comply with the pilot scale specification(s). 
Clearance of a particular novel food will usually be conditional upon its 
complying with the product and/or process specifications of the material 
to which the test data relate and possibly upon the inclusik n of further 
criteria within the specification(s). 
Chemical composition 
7. A thurough understanding of the product and its production process 
will point to potential problems (see paragraphe 2-4 of Part 2). Thcrefore, il 
might be appropriate for suitable chemical analysis of the nove) food to 
precede any biological evaluation. It is not possible to provide a check-list of 
necessary chemical studies to cover all nove) foods but some guidance is given 
in the following paragraphs; aiso MAFF might be able to advise. However, 
chemical analysis need not be regarded as a routine procedure; much will 
depend on the nature of the product. 
8. If the crude protein, total fat or carbohydrate constitutes more than 
about 10% of the dry malter of the novel food, these components may need 
to be more fully investigated as follows - 
a. Crude protein should be examined for the true protein and 
non-protein nitrogenous material. Individual amino-acids should be 
deterrnined as should any unusual or toxic amirio-acids if their 
presence is suspected. (D-amino-acids may be suspected, for example, 
in bacterial proteins, and lysinoalanine in proteins which have been 
subjected to alkaline processing conditions). Available lysine 
measurement is useful in determining whether proteins have undergone 
severe degradation during processing. Non-protein nitrogenous 
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b. Total fat should be examined for saponifiable and 
nonsaponifiable components. A full fatty acid spectrum 
known toxic fatty acids and the amounts of saturated, 
mono-unsaturated and polyunsaturated fatty acids. This 
should include an assessment of fatty acids with trans double 
bonds in the monoenoic and polyenoic fractions, cis, cis, 
9, 12-octadecadienoic acid and fatty acids with chain lengths 
of 22 and over, both mono- and polyenoic together with 
peroxidised and degradation products of polyunsaturated fatty 
acids. 
should be determined. Particular attention should be paid to 
the presence o eDids sterols cvclic fatty acids and 
el; f i brn and c. Total carbohydrate should be examined for availability. The non-metabolisable fraction (eg fibre ehitie 
h i t. i n) n nd a 1 :n 1-nnenc) should be subjected to detailed chemical analysis. 
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9. Aller aas ring, t re novel food should be analysed for the presence of 
toxic metals (eg Iead, arsenic). Depending on ils intended use, analysis for 
metals of nutritional significance (eg iron, zinc, calcium) may be appropriate. 
10. The vitamin content of the nove) food should be determined if the 
presence or absence of particular vitamins is likely to be nutritionally 
significant. 
11. If the nature of the nove) food or the nove) process indicates the 
possible presence of naturally occurring or adventitious antinutritional 
factors (phytate, trypsin inhibitors etc) or toxins (haemagglutinins, 
mycotoxins etc), the product should be analysed for them specifically, by 
chemical techniques in the first instance. Biological tests, either as part of the 
nutritional evaluation in the case of enzyme inhibitors or more specifically 
as part of a mycotoxin screening programme, will provide useful back-up 
evidence concerning the presence or absence of these contaminants. 
NUTRITIONAL STUDIES 
Introduction 
12. Nutritional studies may be necessary to forecast the likely impact 
of the nove) food on the nutritional status of consumers. If the novel food is 
expected to play an important dietary role, the results of nutritional studies 
in animais should be verified in human subjects. The nutritional 
consequences of the introduction of a novel food into the diet can be judged 
only in the light of information about its intended uses. As much 
information as possible should iherefoie be obtained about potential markets 
and uses and the likely maximum consomption by particular population 
groups should be estimated (see paragraph 4 of Part 2). If the novel food 
would replace a traditional food in the diet, any consequential changes in 
dietary nutrient intake will need consideration. 
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13. In 1972 the Committee on Medical Aspects of Food Policy 
recommended that "any substance promoted as a replacement or alternative 
to a natural foori should be the nutritiona) equivalent in ail but unimportant 
aspects of the natural food which it would sirnulate". Accordingly, clearance 
of a novel food expected to form a significant part of the diet may be 
conditional upon the food being fortified. 
14. Nutrient imbalance and palatability problems during toxicological 
studies (particularly when high levels of the nove) food are incorporated into 
animal diets) can give rise to misleading conclusions. Nutritional studies will 
be necessary beforehand to ensure that the test diets will be correctly 
balanced as regards botte macronutrients (eg protein, fat, carbohydrates and 
metabolisable energy) and micronutrients (eg vitamins and minerais). 
Intended use 
15. If the nove) food is likely to be used as a replacement for or an 
alternative to a traditional food, it will need to be assessed with particular 
care. Nutritional data on the nove) food should be compared with data on 
the traditional food. The dietary significance of the traditional food should 
be established using the National Food Survey or other appropriate means. 
The influence (beneficial or detrimental) of the introduction of the nove) 
food on the nutrient composition of the diet as a whole should be identified 
particularly in respect of groups such as children, the elderiy and "captive 
populations" eg hospital patients and schooichildren. 
Effects on nutrients 
16. The nutritional value of the nove) food should be assessed initially 
from its chennical composition in respect of both macronutrients and 
micronutrients, taking into account the effect of any further cooking or 
processing (including when used as an ingredient in food) and of storage. The 
possible influence of components in the nove) food, such as antinutritional 
factors (eg inhibitors of enzyme activity or minerai metabolism) on the 
nutritional value or keeping quality of the remainder of the diet should also 
be established. 
In vivo studies 
17. Dependirrg on the nature and intended uses of the nove) food, studies 
in animais may be needed to supplement the chemical studies. If the nove) 
food is likely to form a significant part of the human diet, in vivo studies will 
usually be appropriate to determine its metabolisable energy. If the novel 
food is intended to be an alternative significant supply of protein, tests on its 
protein qualitv as part of the diet will be necessary. ln vivo studies will also 
be needed when it is appropriate to determine: a. the availability of vitamins 
and minerals in the nove) food in comparison with the food it would replace; 
b. the nove) foods' components' effect on any added minerals, should any 
components substantially reduce the minerai availability; and c. any 
interaction the nove) food might have with other items of the diet that would 
reduce the nutritional value of the diet as a whole. 
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18. If the novel food is expected to play an important role in the diet, il 
may be necessary to verify that the results of animal experiments can be 




19. As explained in the following paragraphs, special considerations apply 
in the toxicological testing of novel foods, especially when they might 
constitute a significant proportion of the human diet. In particular - 
a. The traditional method of assessing the safety of a food 
additive, ie allowing a one hundred-fold margin between the 
maximum amount of the additive likely to be consumed in the human 
diet and the maximum amount which has no toxic effect when fed to 
animais, clearly cannot be applied to novel food which would 
constitute more Chan one per cent of the human diet. In any case, 
there are practical limits to the amounts of certain foods whiclt can be 
added to animal diets without adversely affecting the animais' 
nutritional status and health. 
b. A novel food, once il has been adequately tested in 
appropriate animal and in vitro systems, should always undergo 
tolerance testing, including monitoring for possible allergenicity in 
small groups of normal human volunteers under controlled conditions 
and under medical supervision. 
Studies in laboratory animais 
20. The general principles of animal husbandry to be adopted when 
assessing the safety of novel foods are set out in the DHSS "Guidelines for 
the Testing of Chemicals for Toxicity" (HMSO, 1982). This document 
should also be consulted for further details of the tests discussed in 
paragraphs 25-35. Reference should also be made to the documents 
mentioned below for certain details of specific tests. 
21. Before starting animal studies, il is desirable to investigate the 
palatability of the test diet in the test animais. If a palatability problem is 
encountered, il may be necessary to increase the amount of novel food to the 
required level gradually. Paired-feeding techniques should be used if the 
problem cannot be overcome. 
Metabolic atudies r-,-, 
22. As foods are usually complex mixtures of chemicals, studies on the 
metabolic fate of every constituent of the nove) food would be impracticable. 
However, if il is suspected that contaminants or minor components are the 




investigated. Also, if the nove) food, or a major component of it, consists of 
a new chemical compound which does not normally occur in the diet (eg a 
novel carbohydrate), studies of the metabolic face of the new compound wili 
be appropriate. 
23. Changes in normal excretory functions caused by the nove) food will 
be relevant, and analysis of urine and faeces may give important information. 
For example, a novel food may alter the gui fiora drastically, or may 
encourage preferential Ioss of a minerai or vitamin to the detrirnent of the 
good heaith of the study animais. 
Acute toxicity studies 
24. As a novel food will usually consist mostly of compounds unlikely to 
produce acute toxic effects (carbohydrates, lipids and proteins), acule 
toxicity studies will normally be inappropriate. 
Sub-acute toxicity tests 
25. The novel food's safety should be confirmed by sub-acute toxicity 
studies preferably in a rodent species and in one or more other species. The 
studies should be started shortly alter the animais are weaned and extend 
throughout the period of rapid growth (a study period of 90 days will be the 
normal duration but this may have to be varied, eg a longer period may be 
necessary in the case of longer-lived species.) 
26. The nove) food should be fed to different groups of animais at a 
minimum of two levels of incorporation into the diet. A control group, 
which is not fed any of the nove) food, must be included in the study. The 
higher level of incorporation should be set according to the likely level of the 
novel food in the human diet. In ail cases this level must be substantially in 
excess of the anticipated exposure level in man, which in some cases will 
imply feeding at the maximum practicable level. The second level of 
incorporation should be set appropriately between the high-dose level and the 
nil-dose level of the control groups. The inclusion of a minimum of two 
separate groups of animais receiving the nove) foods at different levels in the 
diet will facilitate distinction between dose-related (toxic) and non-specific 
effects. Numerous dietary incorporation levels in animal experiments will not 
generally be of use since the establishment of a precise no-adverse-effect level 
is inappropriate in the safety assessment of a novel food on account of the 
impracticability of achieving an adequate safety margin between Il o no-effect 
level in animais and the expected consumption of the nove) food in humons 
(see paragraph 19a). 
27. It must be ensured that the nove) food does not distort the nutritionai 
status of the test animal and that the test and control diets have the saine 
nutritive value in terms of both macronutrients and micronulrients. 
Comprehensive nutritional analyses of the nove) food and of the standard 
laboratory diet should therefore be obtained to determine any need, in the 
preparation of the diet for the test group of animais, to supplement or reduce 
any of the standard diet components when mixing in the nove) foodi. 
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28. Animais should be observed regularly for effects on1behaviour and 
state of heaith. At reasonable intervals throughout the study, data should be 
obtained from ail the animais on body weight, food and water consomption. 
In addition, it will generally be useful to obtain data on haematological 
parameters, ophthalmic examination, blood chemistry, urinalysis and faeces 
analysis and it may sometimes be necessary to measure hormone levels and 
minerai and vitamin excretory levels. Any test thought appropriate to the 
bioloqical properties of the nove) food should also be included. Data on 
organ weighis, gross pathology and histopathology should be obtained from 
ail the animais ai the end of the study period. Histological studies should be 
performed in hie control and high-dose groups of animais and, if any 
histological abnorrnalities are found, in the intermediate-dose group also. As 
it is not possible to have a large safety factor between the quantity ingested 
by the test animal and the likely human exposure, it is particularly important 
that tue parameters for assessing the nove) food are chosen carefully to 
inciude monitoring of ali its possible toxic effects. 
Long-terin toxicity and carcinogenicity tests 
29. The need for long-term animal feeding studies will depend on the 
nature of the novel food. In many cases a long-term study could be omitted 
provided the results of sub-acute toxicity and mutagenicity studies were 
satisfactory, but in others, especially if the raw material or the process is 
particularly novel, a long-term study will be needed. When a long-term study 
is indicated, a sub-acute study will not necessarily be required, but it might be 
advisable to conduct one to facilitate the planning of the long-term study. 
30. Long-term studies should be performed over a major part of the test 
animais' lifetime so that normally 50-80% of animais will have died from 
causes other than toxicity attributable to the test material Mien the experi- 
ment is terminated. This would be about two years in rats and about 18 
months in mice and hamsters which are the most commonly used species in 
long-term studies. Strains of animais which do not have a high background 
incidence of spontaneous tumours, but which are reasonably susceptible to 
known carcinogens, should be chosen in order to optimise tire study for the 
detection of any carcinogenic effects of the nove) food. More details about 
carcinogenicity studies are given in the DHSS "Guidelines for the Testing 
of Chemicals for Carcinogenicity" (HMSO, 1982). 
31. Main groups should consist of not less than 50 animais of each sex. It 
is advisable that control groups should be larger than test groups. Historical 
data for animais of the came strain, although often useful, should not be 
regarded as a substitule for adequate numbers in the control groups. 
32. Appropriate levels of dietary incorporation of the nove) food should 
be used, following ihe saine considerations as apply to a short-term study 
(see paragraphe 25-28). It is particularly important to avoid distortion of the 
nutritional status of the test animais. 
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Embryotoxicity (including teratogenicity) and reproduction studies 
33. The general principles and techniques of embryotoxicity and 
reproduction siudies are described in numerous publications, for example, 
Appendix 6 of the DHSS "Guidelines for the Testing of Chemicals for 
Toxicity" (HMSO, 1982). The highest practicable dose of nove) food (as 
defined in paragraph 26) should be included, though any distortion of the 
nutritionai of the test animais must be avoided. 
34. If the nove) food is produced by an extremely novel process and/or 
an extremely novel source, a multigeneration study may be necessary. 
A two generation, two litter design would normally be suitable. The physical 
features and behaviour of the offspring should be investigated, and oogenesis 
and spermatogenesis should be monitored. 
Mutagenicity studies 
35. Mutagenicity tests are designed to measure genetic damage. While 
sot ail mutagens are carcinogens and some carcinogens are sot mutagens, 
there is a broad correlation between the ability 1o induce genetic damage 
and the ability to induce cancer. Aiso, mutagenic damage to the germ cells 
may itself present a hazard to future generations. There are problems in the 
interpretation of mutagenicity tests on novel foods, particularly in view of 
the presence of numerous mutagens in naturally-occurring foodstuffs. 
Nevertheless, such studies may be valuable and, whether or sot long-term 
toxicity studies are undertaken. mutagenicity studies will be needed on the 
novel food. The DHSS "Guidelines for the Testing of Chemicals for 
Mutagenicity" (HMSO, 1981) details the 'basic package' of recommended 
tests. In vitro mutagenicity testing of the nove) food may particular 
problems owing to the presence in the growth medium of nutrients from the 
food, making il necessary to use special bacterial strains or suitab:e extraction 
procedures prior to testing. 
STUDIES IN HUMANS 
Introduction 
36. Before embarking on human studies (other than for evaluation of 
palatability), the nove) food must have been shown to cause no adverse 
effects in animais. The necessary amount of testing in animais will depend on 
the degree of novelty of the food, but for extremely noves products a 
minimum of sub-acute feeding studies in two species and relevant 
mutagenicity tests will be essential. 
37. Il would be acceptable for the nove) foodl to be tested in humas 
volunteers without any studies on ils effects on reproduction and ils 
embryotoxicity, provided women of child-bearing age were excluded and 
provided il had otherwise been adequately tested. However, tests in animais 
for effects on reproduction (see paragraphe 34-35) will normally be necessary 
before the food is used in a large-scale acceptability and marketing 
trial. 
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The selecti.nn of variables to be mea:;nred mav be I1 
influenced by the renttl.ts of the ini,mil FtudieF. 
38. Ail studies carried out on humas subjects must take into account sot 
only scientific objectives but also ethical and legal considerations (see 
Appendix 10 of the "Guidetines for the Testing of Chernicals for Toxicity" 
(HMSO, 1982). This is particularly important when testing a novel food, 
because there is no direct benefit to the participants. 
39. In order to minimise the number of volunteers exposer] to the novel 
food in il ? early stages of ils development, all possible information should be 
obtained trom eactt ,,study. Throughout each experiment regular urinalyses, 
faecal analyses riica'1 chemical and haematological investigations, and renal 
and hepatic function lests should be performed, together with any relevant 
specialised tests which allow the monitoring of specific organ function. 
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Preliminary single-dose studies 
40. Il is generally advisable that the initial human study should involve 
the feeding of a single meal containing the nove) food ai a known dose level 
to one volunteer ai a time. Time should be allowed for any reactions to show 
hefore the test dose is given to another volunteer. The resutts of the study 
might make il possible to predict likely effects in man and to choose more 
suitable animal models for long-term studies. 
Further studies in humans 
41. When the nove) food lias been shown to have no harmful effects 
when fed in single doses, a study involving the feeding of the nove) food for 
a short period (initially about four weeks with follow-up studies of longer 
duration) should be performed- Different diets, incorporating different levels 
of the nove) food, should be fed to different groups of volunteers. The 
dietary levels should be related to the anticipated levels of human exposure. 
Each group should consist of a sufficient number of volunteers to allow 
reliable statisticat analysis of the resutts. Ail studies should include 
concurrent control groups receiving a diet not incorporating the nove) food. 
Those in the control groups should be of similar age, size, sex, alcohol intake 
and smoking habits to those in the test groups. Each test group and ils 
paired control group should be fed diets which are as similar as possible. 
42. ln addition to having control groups, il may be useful to organise 
studies in which the test groups are fed diets incorporating and sot 
incorporating the nove) food in sequential periods, so that each volunteer 
acts as his own control: blind crossover trials are the most satisfactory. 
43. Retrospective analysis should be avoided; instead, a careful note 
should be made ai the time of ail reactions experienced by controls and 
volunteers in case they are later seen to have a relevance to the novel food. 
Particular attention should be paid to gastrointestinal symptoms and possible 
allergic reactions, so that an assessment of the digestibility of the nove) food 
and of the volunteer's tolerance to il can be made. 
44. If the nove) food is intended for use by a certain community or 
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section of the community (eg in a particular country, or by diabetics), ai 
least one sturly should be conducted in the group of people for whom the 
food is intended. 
45. If the nove) food has been tolerated well by the volunteers ai fixed 
dietary levels, it may be useful to feed it ad libitum for a short period of time 
in order to assess its acceptability. 
Health monitoring of employees 
46. The health of workers coming into contact with the nove) food (eg 
laboratory staff, woikers in the manufacturing plant) should be monitored, 
not only because they are dealing with an incompletely tested (and therefore 
potentially harmful) substance,' but also because adverse effects (eg 
allergenicity) of the novel food may be revealed. The state of the food when 
exposure occurs will be significant; for example, the risk of inhalation of food 
particles while handling the raw material may present an increased risk of 
allergic and other reactions developing. Thus, it should be noted whether 
laboratory and manufacturing staff are exposed to the novel fc od in its raw 
or cooked suite. or both. 
Allergenicity studies 
47. It may be necessary to conduct allergenicity studies on the nove) food 
because of ils composition (eg highly proteinaceous) or because the - esuits of 
animal or human feeding studies suggest that the food might produce allergic 
effects in nome people. However, one way of detecting any induced 
allergenicity in the exposed population during pre-marketin,,,tr. l s to 
arrange for a particular standardised antigen made from agcâo% onent of 
the nove) fond to be included in the screening profile used in a local allergy 
clinic. This is usually best organised through a specialised allergy testing unit. 
In order to detect possible induced allergenicity of the nove) food in the 
general population, it will generally be essential to monitor a large number of 
people. Where allergenicity is suspected, types of immunological tests 
required to clarify the situation should be established in consultation with 
relevant specialists. 
Large-scale acceptability and marketing trials 
48. When the nove) food's safety has been demonstrated by the studies 
indicated ahove, large-scale acceptability and marketing trials should be 
undertaken. 
49. For products of extreme novelty, the local medical services 
responsible for the areas where the nove) food is to be tested should be 
alerted so that they may take it into account when evaluating any unusual 
disease patterns that may appear during or alter the test period. As large 
numbers of people will be involved in the trials, it may be possible to obtain 
information about any rare adverse reactions to the novel food (eg allergic 
reactions) which might not have been observed in earlier human studies. The 
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extent to which health monitoring should be performed will depend on the 
nature of the nove) food and the results of previous toxicological 
investigations, but in any case it will probably be advisable to arrange for 
basic medical surveillance of the individuals involved. To ensure that all 
information relevant to safety assessment in a large-scale trial is obtained, 
one medical practitioner should be given overall responsibility for the health 
monitoring, and it may also be useful to restrict the trial to a defined 
geographical area. 
Special groups 
50. In addition to estahlishing the safety of the nove) food in the general 
poperation special attention needs to be paid to vulnerable groups such as 
pregnant women, children, the elderly, diabetics and any other group thought 
to be especially at risk, eg subjects with an inborn error of metabolism. (The 
severity of the risk will dictate the protective measures necessary, eg 
appropriate labelling might be adequate.) 
Interactik n with drugs 
51. Particular tare should be taken to establish whether the nove) food 
might interfere with the absorption or action of commonly-used drugs. If 
there appears to be such a possibility, appropriate pharmacological studies 
should be performed. 
Progress in the future 
52. As new methods of investigation become available in special areas, eg 
allergy testing, they should be incorporated into the above test procedures as 
and where appropriate. 
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COUNCIL DIRECTIVE 
of 18 April 1983 
on the fixing of guidelines for the assessmen of certain products used in animal nutrition 
(83/228/EEC) 
THE COUNCIL OF THE EUROPEAN COMMUNITIES, 
Having regard to the Treaty establishing the European 
Economic Community, 
Having regard to Council Directive 82/471 /EEC of 
30 June 1982 concerning certain products used in animal 
nutrition ('), and in particular Article 7 thereof, 
Having regard to the proposai from the Commission, 
Whereas Directive 82/471/EEC provides chat the 
products belonging to certain groups must be examined 
on the basic of a dossier forwarded officially to the 
Member States and the Commission; 
Whereas such dossiers must make it possible to verify that 
the products in question comply with the general 
principles laid down in the Directive in respect of the 
inclusion of new products in the Annex; 
Whereas it has been found necessary to provide for the 
dossiers to be compiled in accordance with common 
guidelines defining, for each principle, the scientific data 
which make it possible to identify and characterize the 
products concerned and the ,,tudies necessary in order to 
evaluate their nutritional properties and biological 
effects; whereas these guidelines must be applicable on 
the date on which Directive 82/471/EEC itself enters 
into force; 
Whereas the guidelines are intended primarily as a general 
guide; whereas, depending on the nature of the product or 
its conditions of use, the extent of the studies necessary in 
order to evaluate its properties or its effects may vary; 
Whereas the guidelines have been drawn up on the bases 
of present scientific and technical knowledge and they 
may be adapted if necessary to any developments in this 
sphere, 
FIAS ADOPTED THIS DIRECTIVE: 
Article 1 
Member States shah prescribe that the dossiers on the 
products listed in points 1.1 and 1.2 of the Annex to 
Directive 82/471 /EEC are to be compiled in accordance 
with the guidelines set out in the Annex hereto. 
Article 2 
Member States shah bring into force the laws, regulations 
or administrative provisions necessary in order to comply 
with this Directive by 13 July 1984 at the latest. They 
shah forthwith inform the Commission thereof. 
Article 3 
This Directive is addressed to the Member States. 
Donc at Luxembourg, 18 April 1983. 
For the Council 
The President 
1. KIECHLE 
(1) OJ NoL213, 21. 7. 1982, p. 8. 
No L 126/24 Official Journal of the European Comtnunities 
ANNEX 
GUIDELINES FOR THE ASSESSMENT OF CERTAIN PRODUCTS USED IN ANIMAI. 
NUTRITION 
General aspects 
These'guidelines' constitute a guide intended to establish dossiers on products listed in items 1.1 and 1.2 of the Annex to Directive 82/471 /EEC, which have been obtained from culturing micro-organisms and which are likely to be admitted as a new source of proteins in animal nutrition. These dossiers should enable an assessment of such products based on the prescrit state of knowledge and should ensure their compliance with the fundamental principles laid down for permitting their use, which are the subject of Article 6 (2) of the abovementioned Directive. 
AI] the studies outlined in this document may be required and, if necessary, additional information may he requested. As a general rude, al] the information necessary to establish the identity of the micro-organism and the composition of the culture medium, and also the manufacturing process, characteristics, presentation, conditions of use, methods of determination and nutritional properties of the product must be provided. The same applies to the information necessary to assess the tolerance of the product by the target species and the risks for man and the environnent, which could result directly or indirectly from the use of the product. The toxicological studies required for this purpose will depend on the nature of the product, the animal species concerned and the metabolism of the product in laboratory animais. 
The documentation to be provided should include detailed reports, presented in the order and with the numbering proposed in these guidelines and should be accompanied by a summary. The omission of any proposed studies should be justified. The publications quoted as references should be attached. 
Observations 
The term'product', as used in these guidelines, refers to any proteinaceous product in the state in which it will be presented as feedingstuff or component of a feedingstuff. 
Any modification in the manufacturing process or in the conditions of use of a product will require notification and, if necessary, additional documentation for a new assessment. 
Presentation of studies 
1. Micro-organism, culture medium and manufacturing process, characteristics of product, presentation ànd conditions of use, methods of determination 
II. Studies on the nutritional properties of the product 
III. Studies on the biological consequences of the use of the product in animal nutrition 
IV. Other relevant studies 
SECTION I 
MICRO-ORGANISM CULTURE MEDIUM AND MANUFACTURING PROCESS, CHARACTERISTICS OF PRODUCT, PRESENTATION AND CONDITIONS OF USE, METHODS 
OF DETERMINATION 
1. MICRO-ORGANISM 
1.1. Classification, provenance, morphology, biological properties, any genetic manipulation. 
1.2. Innocuity, possible survival outside the fermenter and any environmental conséquences. 
1.3. Constancy and purity of strains cuitivated. Methods used to check these criteria. 
2. CULTURE MEDIUM AND MANUFACTURING PROCESS 
2.1. Composition of substrate, added substances, etc. 
2.2. Manufacturing, dessication and purification processes. Devitalizing process for micro-organisms. Methods used to check the constancy of composition of the culture product and the detection of any chemical, physical and biological contamination during production. 
2.3. Technical proccsses of preparation for use. 
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3. CHARACTERISTICS OF PRODUCT 
3.1. Physical and physico-chemical properties: macro- and micro-morphology, particle size, density, 
specific weight, hygroscopicity, solubility, electrostatic properties, etc. 
3.2. Chemical composition and characteristics. 
3.2.1. Content of moisture, crude protein, crude fat, crude cellulose, crude ash, carbohydrates. Limits of 
variation of these contents. 
3.2.2. Content of total ammonium, amide, nitrate and nitrite nitrogen, nucleic acids, protein. Qualitative 
and quantitative composition of total and free amino acids, and purine and pyrimidine bases. 
3.2.3. Qualitative and quantitative composition of total lipids: fatty acids, non-saponifiable matter, lipid 
soluble pigments, phospholipids. 
3.2.4. Composition of the carbohydrate fraction. 
3.2.5. Qualitative and quantitative composition of inorganic components. 
3.2.6. Qualitative and quantitative composition of vitamins. 
3.2.7. Qualitative and quantitative composition of the other constituents: additives, residues of substrate 
and solvents, other potentially harmful residues of the ntetabolism of the substrate, of the culture 
medium, of the manufacturing process. 
3.3. Microbiological contamination of the product. 
3.4. Behaviour and stability of the product, as such and when mixed with feedingstuffs in current use, 
during storage. 
4. PRESENTATION AND CONDITIONS OF USE 
4.1. Proposed names of marketing the product. 
4.2. Proposed formulations for marketing the product. 
4.3. Intended use of the product in animal nutrition. Intended concentrations in the complete 
feedingstuffs and in the intended quantities in the daily rations for the animal species 
concerned. 
5. METHODS OF DETERMINATION 
Qualitative and quantitative methods for determination of the product in complete and 
complementary feedingstuffs. 
NB: Description of these methods should be accompanied by information as to specificity, 
sensitivity, limits of detection, margin of error, possible interferences by other substances. 
Samples of the product in its various proposed presentations should be available. 
SECTION II 
STUDIES ON THE NUTRITIONAL PROPERTIES OF THE PRODUCT 
1. ASSESSMENT OF PROTEIN VALUE 
1.1. Chemical, biochemical and microbiological studies. 
1.2. Studies on laboratory animais, compared with reference proteins. 
2. STUDIES ON TARGET SPECIES 
The following studies should be performed on each target species in comparison with a control group receiving, under the same conditions of nutritional balance, a diet in current use containing equivalent amounts of protein nitrogen, for ruminants of total nitrogen. 
2.1. Protein and energy supplementation value of the product in the rations under the proposed conditions of use at various physiological stages of the animais (e.g. growing period, pregnancy, 
laying). 
2.2. Influence of the product under the proposed conditions of use on growth rate, feed conversion rate, morbidity, mortality. 
2.3. Optimum nutritional levels of incorporation of the product in the rations. 
2.4. Effect of the product under the proposed conditions of use on the technological, organoleptic or other qualities of edible producrs of animal origin. 
3. EXPERIMENTAL CONDITIONS IN THE STUDIES ON TARGET SPECIES 
Give a detailed description of the tests performed and provide the following data: 
3.1. Species, breed, age and sex of the animais, identification procedure. 
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3.2. Number of test and control groups; number of animais in each group (the number should be large enough for statistical analysis using suitable statistical parameters). 
3.3. Levels of incorporation of the product, qualitative and quantitative composition of the ration and its analysis. 
3.4. Location of each experiment, physiological state and animal health conditions, rearing conditions 
(these should reflect those used in practice in the Community). 
3.5. Exact duration of testing and date of the analyses performed. 
3.6. Adverse effects which occurred during the experiment and time of their appearance. 
SECTION 111 
STUDIES CONCERNING THE BIOLOGICAL CONSEQUENCES OF THE USE OF THE PRODUCT 
IN ANIMAL NUTRITION 
The studies outlined in this section are intended to permit assessment of the safety in use of the product in the target species, and of the risks for man and the environment which could result directly or indirectly from this use. The toxicological studies required for this purpose will depcnd on the nature of the product, the animal species concerned, and the metabolism of the product in laboratory animais. 
1. STUDIES ON TARGET SPECIES 
The following studies should be performed on each target species in comparison with a control 
group receiving, under the saure conditions of nutritional balance, a diet in current use containing equivalent amounts of protein nitrogen, for ruminants of total nitrogen. 
1.1. Maximum incorporation rates of the product in the daily ration without producing any adverse effect. 
1.2. Possible effect of the product on fertility and reproduction, if appropriate. 
1.3. Effects of ingestion of the product under the proposed conditions of use on micro-organisms of the flora of the alimentary tract and on colonization of pathogens in the alimentary tract. 
1.4. Investigation under the proposed conditions of use of possible residues of the product (substrate, 
culture medium, solvents, contaminants) in edible products of animal origin. 
1.5. Investigation under the proposed conditions of use of possible residues of the product (substrate, culture medium, solvents, contaminants) in excreta. 
2. STUDIES ON LABORATORY ANIMALS 
2.1. Metabolism 
Fate of the product in the animal: absorption, accumulation, biotransformation, elimination. 
2.2. Mutagenicity 
Investigations of potential mutagenicity due to contaminants (in particular mycotoxins and bacteria) or residues of the product (substrate, culture medium, solvents) including in vitro screening tests using metabolic activation systems. 
2.3. Toxicological studies 
The following studies should be performed in comparison with control groups receiving, under the saure conditions of nutritional balance, a diet in current use containing equivalent amounts of protein nitrogen. Toxic effects should bc investigated to elucidate their cause and mechanisms and to ascertain that they do not result from nutritional imbalance or from an overdosage of the product in the diet. 
2.3.1. Subchronic toxicity (at least 90 days) 
In general, these studies should be carried out on two animal species, one of which being a rodent. The product should be administered in the daily ration in at least two levels of incorporation. These should be chosen so as to determine, if possible, a no-effect level and a level showing some adverse 
effect. The animal groups should contain an adequate number of subjects of each sex. A control group should always be included. 
All relevant biological data should be recorded at appropriate intervals, particularly data on growth rate, feed consumption, haematology, urine analysis, biochemical parameters, mortality, organ 
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weights, gross patholog, and hisi p.itlntlogy of niajor organs and tissucs. f hc results should be 
presented in detail and, as far as possible, should includc statistical assessment. 
23.2. ('brunit toxicity 
In general, t hronic toxicity studios should be carried out on two animal species, one of which being 
a rodent. The product should be admininstered in the daily ration in at Ieast two levels of 
incorporation. Experimena, should extend for a minimum of two vears in the rat or 80 weeks in 
niice. The animal groups should contain an adequatc nuntbcr of suhjects of cach sex. A control 
group should alsvays be tncludcd. 
The biological examinations mentioned under point 2.3.1 should be carried out preferably on a 
small satellite group of aninials (a group separated fi an and dependent upon the main group) at 
appropriatc inters ils throughout the esperinient and on the sur%iving animais at rite end of the 
experinient. 
2.3.3. Carciriogenicity 
For assessing carcinogcnicity, particular attention should be paid to the tinte of appearance, the 
histological types of any ohserved tumours and their incidence. Any effect on the incidence of 
tumours and/or the incidence or progress of discales should he assessed by reference to control 
groups, as intlicated in paragraph 2.3. The results should bc presented in detail and, as far as 
possible, should include statistical assessment. 
2.4. Other studies 
Reproduction studies should extend over at least two filial generations and may be combined with 
embryotoxicity including teratogenicity studies. Particular attention should be paid to fertility, 
fecundity and observation on post-natal development of inters. Any other method that is 
scientifically justifiable aiid likely to produce measurable results (e.g. relay toxicity) may bc 
provided. 
2.5. Experimental conditions in the studies on laboratory animais 
Give detailed description of the tests performed and provide the following data: 
2.5.1. Species, breed, strain and sex of animais. 
2.5.2. Number of test and control groups, number of animais in cach group (the number should be large 
enough for statistical analysis using suitable staustical parameters). 
2.5.3. Levcls of incorporation of the product, qualitative and quantitative composition of the ration and 
its analysis. 
2.5.4. General rearing conditions throughout the period of testing. 
2.5.5. Exact duration of testing and date of examinations performed. 
2.5.6. Rate and timing of deaths for the various test groups. 
2.5.7. Clinicat symptoms and pathological alterations which occurred during the experiment and time of 
their appearance. 
STUDIES CONCERNING THE ENVIRONME.NT 
Depending on the nature of possible residues of the product (substrats, culture medium, solvents, 
contaminants) in excreta of target species, data on the face of these residues in manure, soit and 
water and also their effects on soif biology, plan growth and aquatic life may be required. 
SECTION I V 
OTHER RELEVANT STUDIES 
Depending on the nature and the conditions of use of the product, data on allergie effects, on irritation of 
the skin and mucus membranes of rhe eye, respiratory or digestive tract may he required to assess possible 
risks in handiing the product and to prevent thon. 
SAFETY OF NOVEL FOODS MEETING 
APPENDIX 8 
NOVEL F00DS - ESTIMATED TESTING COSTS 
APPENDIX 8 
NOVEL FOODS - ESTIMATED TESTING COSTS 
1. Introduction 
The testing cost estimates discussed here for novel foods are based 
on the assumption that individual products will require different levels 
of toxicity testinq depending on their degree of novelty, the novelty of 
the raw materials used in their production and the processes involved. 
Therefore, to give maximum flexibility combined with the ability to 
recognize unacceptable toxicity as inexpensively as possible, the costing 
of the toxicity program is arranged sequentially as a series of programs 
of increasing colt and increasing duration. The level to which it is 
necessary to undertake toxicity testinq of an individual novel food will 
be a difficult decision using the advice of hiqhly skilled nutritionists, 
analysts and toxicologists in combination with those responsible for 
product regulation. 
It is visualized that developers of novel foods may wish to take the 
product to one of the many reputable commercial establishments for 
toxicity testing. Approximate testing costs are qiven in Canadian 
dollars and it should be realized that these will vary between one 
testing house and another, with the standards to be met as well as with 
the amount of testing that is required. For example, if Good Laboratory 
Practice standards are required this will inevitably raire costs by 
25-30% over those estimated here. 
II. Program 
a) Microbial Program 
This program represents a minimum to establish freedom of the novel 
food from microbial contamination that might lead to human disease. 
Total bacteria, Escherichia coli, salmonella, 2,000.00 
ciostridium perfringes and coagulase-positive 
staphylococus. 
b) Chemical Program * 
The tests outlined here are a minimum to ensure that the product is 
not chemically contaminated. Knowledge of the product may suggest other 
specific analyses based on the degree of contaminants during processing 
or storage. 
(i) Tests for solvent residues (such as hexane and 1,000.00 
other organic solvents, inorganic acids and alkalis) 
and known toxic factors such as glucosinolates, 
gossypol, aflatoxins, lysinoalanine, heavy metal 
contamination. 
(ii) Tests required to define substrates in the 2,000.00 
case of SCP products (such as chain length and 
purity, presence of any potentially carcinogenic 
polycyclic aromatic hydrocarbons, etc. 
c) Nutritional Program 
The purpose of this program is to ensure that the novel food is 
nutritionally acceptable and does not contain components such as novel or 
unusual fatty acids whose toxicity is not adequately known. 
Proximate composition, amino acid profile, protein 6,000.00 (Total) 
efficiency ratio, minerai analyses including heavy 
metals, vitamin analyses inciuding 15 vitamins, fatty 
acid composition, reducing sugars. 
* The colts of microbial and chemical testing listed above represent 
absolute minimum colts for basic testing. Actual costs may range 
considerably higher depending on the complexity and length of tests 
deemed appropriate. 
d) Toxicity Program 
The toxicity program is performed in experimental animais and is an 
essential precursor of the clinical tests described in the next section. 
A very limited program is suggested including a subchronic study, a 
reproduction study in one or three generations, a genotoxicity test 
(Ames) and a chronic study designed to determine degenerative changes as 
well as cancer. This does not in any way attempt to cover the possible 
complete range of tests which might also include tests for behavioral 
deficits or immunotoxicity, for example. 
Subacute study (one species) 40,000.00 
Reproduction study (one species, one generation) 40,000.00 
Reproduction studies (one species, three generations) 120,000.00 
Short-term tests for carcinogenicity (Ames Test) 1,200.00 
Chronic toxicity/carcinogenictiy (rat and mouse) 1,000,000.00 
e) Ciinical Program in Humans 
The clinical program is designed to ensure that the novel food that 
appears acceptable from animal based toxicity tests (above) does not 
produce unexpected adverse effects in humans. this program should be 
based in a hospital or clinic and will involve close clinical monitoring 
of the volunteer population exposed to the novel food or placebo. 
Determination of product acceptability and 70,000.00 
physiological tolerance (involving 50 subjects, 
four product intake levels for a period of 60 days). 
Determination of nitrogen balance (involving 8 15,000.00 
subjects fed four protein levels for a period of 
11 days). 
Measurement of various changes, e.g. in amounts 2,000.00 
of albumin, amino acids, uric acid and enzyme 
activity in blood plasma or serum. 
f) Initial Marketing Surveillance Program 
The need may be perceived for a form of population monitoring for 
unexpected adverse effects when the novel food is first introduced to the 
market place. The cost will depend on the complexity of the monitoring 
program. 
III. Testing Packages 
The level of testing required for a novel food will ultimately 
depend on the deqree of novelty, the expected overall consumption rate by 
the population, and expected consumption by high level users (outliers). 
The following gives the estimated costs in Canadian dollars and the 
duration of a number of testing packages. 
Package 1: Microbial and Chemical Tests. Time: 1-2 months 
Minimum: $5,000.00 
A package of this sort might be expected to be done batchwise if a 
large scale production of a novel food is envisioned. Novel foods with 
known or predictable toxic principles would require appropriate specific 
tests (e.g. novel potatoes for solanine). 
Package 2: Microbial, Chemical and Nutritional Tests. Time: 3-4 months 
Minimum: approximately $11,000.00 
Again, this package might form one basis for defining batchwise 
product acceptability in cases such as single cell protein. 
Package 3: Microbial, Chemical, Nutritional and (minimum) Toxicological 
Tests. Time: 14 months Minimum: $92,000.00 
Minimum toxicology testing would consist of subacute study (one 
species), reproduction study (one qeneration) and genotoxicity test 
(one). 
Package 4: Microbial, Chemical, Nutritional and (full) Toxicological 
(including carcinogenicity) Tests. Time: 60 months 
Minimum: $1,172,000.00 
A full toxicological package will consist of subacute study, 
genotoxicity test (one), three generation reproduction study, cancer and 
chronic study. 
Package 5: Microbial, Chemical, Nutritional, (minimum) Toxicological 
and Clinical Tests. Time: 24 months Minimum: $179,000.00 
Package 6: Full Test: Package 4 and Clinical Tests. Time: 70 months 
Minimum: $1,259,000.00 
VI. Conclusion 
The size and scope of the testing data package required for a 
specific novel food raises important and difficult questions at the 
technical, policy and regulatory levels. The requirements set out in 
this text are minimal and should not necessarily be construed to 
encompass all that may be needed in specific circumstances. 
EDITOR'S NOTE: 
Dr. I.C. Munro of the Canadian Centre for Toxicology at the 
University of Guelph suggested that a minimum novel foods testing 
facility might include 15 to 20 scientists with an annual operating 
budget of roughly $5 to $8 million in Canada. Capital costs for 
establishing such a laboratory miqht similarly be in the order of $5 
to $8 million. 
Dr. Munro strongly recommends contract testing of novel food 
products especially in countries where the necessary expertise is in 
short supply. 
